Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Edetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.74 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.78 |
| ▸ | EYA2 | O00167 | 1/20 | 0.78 |
| ▸ | APP | P05067 | 1/20 | 0.78 |
| ▸ | ACE | P12821 | 1/20 | 0.78 |
| ▸ | BLM | P54132 | 3/20 | 0.74 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.74 |
| ▸ | LMNA | P02545 | 2/20 | 0.74 |
| ▸ | TSHR | P16473 | 2/20 | 0.74 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.74 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.74 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.74 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.74 |
| ▸ | DRD1 | P21728 | 1/20 | 0.74 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.74 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.74 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.74 |
| ▸ | DRD3 | P35462 | 1/20 | 0.74 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.74 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Edetic Acid SCHEMBL3881101 | 1.00 | TDP1 (0.78) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL12275301 | 0.97 | TDP1 (0.74) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL14632752 | 0.97 | TDP1 (0.74) | TDP1EYA2APPACEBLM | |
| Pentetic Acid SCHEMBL6913169 | 0.97 | TDP1 (0.79) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL28036095 | 0.97 | TDP1 (0.74) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL8628637 | 0.95 | TDP1 (0.70) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL7150313 | 0.95 | TDP1 (0.70) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL28856674 | 0.91 | TDP1 (0.64) | TDP1EYA2APPACEBLM | |
| Nitrilotriacetic Acid SCHEMBL4638079 | 0.88 | TDP1 (0.58) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL8607480 | 0.88 | TDP1 (1.00) | TDP1EYA2APPACEBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 771 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112300982-B | Hair follicle microarray co-culture system and application thereof in medicine for treating pathological alopecia | 华科同济干细胞基因工程有限公司 | 2022-01-28 | — | — | CN | claimed |
| CN-112342186-B | Culture method of hair follicle stem cells | 华科同济干细胞基因工程有限公司 | 2021-12-28 | — | — | CN | claimed |
| CN-113577389-A | Acellular cartilage material from pig ear cartilage and preparation method and application thereof | 中国医学科学院整形外科医院 | 2021-11-02 | — | — | CN | claimed |
| CN-110354303-A | A kind of antibacterial method of modifying of metallic titanium surface | 北京化工大学 | 2019-10-22 | — | — | CN | claimed |
| CN-107873732-A | The preparation method of one plant growth regulators | 常州市鑫嘉生物科技有限公司 | 2018-04-06 | — | — | CN | claimed |
| CN-107858422-A | Detect the chromosome and gene probe composition and kit of RAEB | 中国医学科学院血液病医院（血液学研究所） | 2018-03-30 | — | — | CN | claimed |
| CN-103239733-A | Integrin targeting drug loaded albumin nanoparticle formulation and its preparation method | UNIV FUDAN SHANGHAI CANCER CT | 2013-08-14 | — | — | CN | claimed |
| US-20110189731-A1 | POLYNUCLEOTIDES ENCODING RECOMBINANT LUBRICIN MOLECULES AND USES THEREOF | WYETH LLC | 2011-08-04 | — | — | US | claimed |
| US-7968327-B2 | Nucleic acid quantitation from tissue slides | AFFYMETRIX, INC. | 2011-06-28 | — | — | US | claimed |
| US-7863434-B2 | Characterization of granulocytic Ehrlichia and methods of use | ANTIGENICS INC. (US) | 2011-01-04 | — | — | US | claimed |
| CN-101294148-B | Method for extracting and purifying high ferro myohemoglobin reductase from myocardium | UNIV NANJING NORMAL | 2010-11-10 | — | — | CN | claimed |
| US-20100088774-A1 | CHARACTERIZATION OF GRANULOCYTIC EHRLICHIA AND METHODS OF USE | ANTIGENICS LLC | 2010-04-08 | — | — | US | claimed |
| US-20100081138-A1 | Nucleotide sequences for the detection of enterohaemorrhagic Escherichia coli (EHEC) | BIO-RAD PASTEUR | 2010-04-01 | — | — | US | claimed |
| US-7588933-B1 | Nucleotide sequences for detecting enterohaemorrhagic Escherichia coli (EHEC) | BIO-RAD PASTEUR (FR) | 2009-09-15 | — | — | US | claimed |
| CN-101294148-A | Method for extracting and purifying high ferro myohemoglobin reductase from myocardium | UNIV NANJING NORMAL (CN) | 2008-10-29 | — | — | CN | claimed |
| US-7109315-B2 | Renilla reniformis fluorescent proteins, nucleic acids encoding the fluorescent proteins and the use thereof in diagnostics, high throughput screening and novelty items | Bryan, Bruce J. (US) | 2006-09-19 | — | — | US | claimed |
| US-5888537-A | LIPOSOMES COMPRISED OF PHOSPHATIDYL CHOLINE, CHOLESTEROL AND PHOSPHATIDYL GLYCEROL, HAVING INTERNAL AQUEOUS PHASE CONTAINING CATIONIC VINCA ALKALOID AND ANION OF LOW MEMBRANE PERMEABILITY | NEXSTAR PHARMACEUTICALS, INC. (US) | 1999-03-30 | — | — | US | claimed |
| WO-1998016545-A1 | THERAPEUTIC PROTEINS | ELI LILLY AND COMPANY (US) | 1998-04-23 | — | — | WO | claimed |
| EP-0835879-A2 | Analogs of obesity proteins and pharmaceutical formulations comprising them | ELI LILLY AND COMPANY (US) | 1998-04-15 | — | — | EP | claimed |
| US-20240209421-A1 | SINGLE-BUFFER COMPOSITIONS FOR NUCLEIC ACID DETECTION | MAMMOTH BIOSCIENCES, INC. | 2024-06-27 | — | — | US | disclosed |
| WO-2024134382-A1 | COMPOSITIONS FOR OPHTHALMOLOGIC DEVICES | JOHNSON & JOHNSON VISION CARE, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| CN-113164577-B | Combination vaccine composition comprising reduced doses of inactivated poliovirus and method for preparing same | 印度血清研究所私人有限公司 | 2024-06-18 | — | — | CN | disclosed |
| CN-117706079-A | Method for directionally labeling biotin polymer by antibody | 四川希格瑞生物技术有限公司 | 2024-03-15 | — | — | CN | disclosed |
| CN-117563016-A | Double-targeting nano liposome drug delivery system and application | 湖北理工学院 | 2024-02-20 | — | — | CN | disclosed |
| US-11827937-B2 | Genetic polymorphisms associated with statin response and cardiovascular diseases, methods of detection and uses thereof | Celera Corporation (US) | 2023-11-28 | — | — | US | disclosed |
| US-11814684-B2 | Genetic polymorphisms associated with coronary events and drug response, methods of detection and uses thereof | Celera Corporation (US) | 2023-11-14 | — | — | US | disclosed |
| US-11793869-B2 | Methods for enterovirus inactivation, adjuvant adsorption and dose reduced vaccine compositions obtained thereof | SERUM INSTITUTE OF INDIA PVT LTD. (IN) | 2023-10-24 | — | — | US | disclosed |
| CN-116920116-A | Catalase-encapsulated nanocapsule, preparation method and application thereof | 上海巴久巴生物技术有限公司 | 2023-10-24 | — | — | CN | disclosed |
| EP-4259822-A1 | SINGLE-BUFFER COMPOSITIONS FOR NUCLEIC ACID DETECTION | Mammoth Biosciences, Inc. (US) | 2023-10-18 | — | — | EP | disclosed |
| US-11788143-B2 | Genetic polymorphisms associated with psoriasis, methods of detection and uses thereof | Celera Corporation (US) | 2023-10-17 | — | — | US | disclosed |
| US-11708610-B2 | Genetic polymorphisms associated with cardiovascular disorders and drug response, methods of detection and uses thereof | Celera Corporation (US) | 2023-07-25 | — | — | US | disclosed |
| US-11639368-B2 | Method for preventing and treating hyperpermeability | APEPTICO FORSCHUNG UND ENTWICKLUNG GMBH (AT) | 2023-05-02 | — | — | US | disclosed |
| US-20230115835-A1 | GENETIC POLYMORPHISMS ASSOCIATED WITH STROKE, METHODS OF DETECTION AND USES THEREOF | CELERA CORP (US) | 2023-04-13 | — | — | US | disclosed |
| US-20230100271-A1 | GENETIC POLYMORPHISMS ASSOCIATED WITH CARDIOVASCULAR DISEASES, METHODS OF DETECTION AND USES THEREOF | CELERA CORP (US) | 2023-03-30 | — | — | US | disclosed |
| WO-2023029161-A1 | NATURAL COLLAGEN MATERIAL, PREPARATION METHOD AND USE FOR NATURAL COLLAGEN MATERIAL | 北京博辉瑞进生物科技有限公司 | 2023-03-09 | — | — | WO | disclosed |
| CN-113679889-B | Acellular matrix composite material and preparation method and application thereof | 杭州贤石生物科技有限公司 | 2022-10-25 | — | — | CN | disclosed |
| CN-114832041-A | Composition with liver protection effect and preparation method thereof | 健茂生物科技股份有限公司 | 2022-08-02 | — | — | CN | disclosed |
| US-11401555-B2 | Genetic polymorphisms associated with stroke, methods of detection and uses thereof | Celera Corporation (US) | 2022-08-02 | — | — | US | disclosed |
| US-20220235418-A1 | Use of Biomarkers for Degenerative Disc Disease | TYUMEN HOLDINGS, LLC | 2022-07-28 | — | — | US | disclosed |
| WO-2022132833-A1 | SINGLE-BUFFER COMPOSITIONS FOR NUCLEIC ACID DETECTION | MAMMOTH BIOSCIENCES, INC. (US) | 2022-06-23 | — | — | WO | disclosed |
| US-20220177969-A1 | Methods for Detecting an increased risk for coronary heart disease | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2022-06-09 | — | — | US | disclosed |
| US-20220154277-A1 | GENETIC POLYMORPHISMS ASSOCIATED WITH CORONARY EVENTS AND DRUG RESPONSE, METHODS OF DETECTION AND USES THEREOF | CELERA CORP (US) | 2022-05-19 | — | — | US | disclosed |
| EP-3959333-A1 | USE OF BIOMARKERS FOR DEGENERATIVE DISC DISEASE | Predictive Technology Group, Inc. (US) | 2022-03-02 | — | — | EP | disclosed |
| CN-112300982-B | Hair follicle microarray co-culture system and application thereof in medicine for treating pathological alopecia | 华科同济干细胞基因工程有限公司 | 2022-01-28 | — | — | CN | disclosed |
| CN-112342186-B | Culture method of hair follicle stem cells | 华科同济干细胞基因工程有限公司 | 2021-12-28 | — | — | CN | disclosed |
| US-11179453-B2 | Immunogenic composition having improved stability, enhanced immunogenicity and reduced reactogenicity and process for preparation thereof | SERUM INSTITUTE OF INDIA PVT LTD (IN) | 2021-11-23 | — | — | US | disclosed |
| CN-113679889-A | Acellular matrix composite material and preparation method and application thereof | 杭州贤石生物科技有限公司 | 2021-11-23 | — | — | CN | disclosed |
| US-20210348232-A1 | GENETIC POLYMORPHISMS ASSOCIATED WITH CARDIOVASCULAR DISORDERS AND DRUG RESPONSE, METHODS OF DETECTION AND USES THEREOF | CELERA CORP (US) | 2021-11-11 | — | — | US | disclosed |
| US-20210346483-A1 | Combination Vaccine Composition Comprising Reduced Dose Inactivated Poliovirus And Method For Preparing The Same | SERUM INSTITUTE OF INDIA PRIVATE LIMITED (IN) | 2021-11-11 | — | — | US | disclosed |
| US-20210332434-A1 | GENETIC POLYMORPHISMS ASSOCIATED WITH CARDIOVASCULAR DISORDERS AND DRUG RESPONSE, METHODS OF DETECTION AND USES THEREOF | CELERA CORP (US) | 2021-10-28 | — | — | US | disclosed |
| CN-113502259-A | Isolated culture method of hair follicle stem cells | 同济大学 | 2021-10-15 | — | — | CN | disclosed |
| US-20210317530-A1 | GENETIC POLYMORPHISMS ASSOCIATED WITH PSORIASIS, METHODS OF DETECTION AND USES THEREOF | CELERA CORP (US) | 2021-10-14 | — | — | US | disclosed |
| US-11124834-B2 | Genetic polymorphisms associated with venous thrombosis, methods of detection and uses thereof | Celera Corporation (US) | 2021-09-21 | — | — | US | disclosed |
| EP-3643792-B1 | DETECTION AND ANALYSIS OF SEQUENCE VARIATIONS IN A TARGET NUCLEIC ACID | FUJIREBIO EUROPE N V (BE) | 2021-09-15 | — | — | EP | disclosed |
| EP-3863665-A1 | COMBINATION VACCINE COMPOSITION COMPRISING REDUCED DOSE INACTIVATED POLIOVIRUS AND METHOD FOR PREPARING THE SAME | Serum Institute Of India Private Limited (IN) | 2021-08-18 | — | — | EP | disclosed |
| EP-3660508-B1 | GENETIC POLYMORPHISMS ASSOCIATED WITH STATIN RESPONSE AND CARDIOVASCULAR DISEASES | CELERA CORP (US) | 2021-08-18 | — | — | EP | disclosed |
| CN-113164577-A | Combination vaccine composition comprising a reduced dose of inactivated poliovirus and method for preparing the same | 印度血清研究所私人有限公司 | 2021-07-23 | — | — | CN | disclosed |
| CN-110455935-B | Quantitative detection method for vanadium valence state | 重庆大学 | 2021-07-02 | — | — | CN | disclosed |
| EP-3132073-B1 | PORTABLE NUCLEIC ACID ANALYSIS SYSTEM AND HIGH-PERFORMANCE MICROFLUIDIC ELECTROACTIVE POLYMER ACTUATORS | STANFORD RES INST INT (US) | 2021-06-30 | — | — | EP | disclosed |
| US-11041209-B2 | Genetic polymorphisms associated with myocardial infarction, methods of detection and uses thereof | Celera Corporation (US) | 2021-06-22 | — | — | US | disclosed |
| CN-107072642-B | Device for obtaining biological material and/or biological information from a sample having a heterogeneous substrate | 拜奥默里克斯公司 | 2021-06-15 | — | — | CN | disclosed |
| US-11028445-B2 | Molecular prognostic signature for predicting breast cancer metastasis, and uses thereof | Celera Corporation (US) | 2021-06-08 | — | — | US | disclosed |
| US-20210164050-A1 | GENETIC POLYMORPHISMS ASSOCIATED WITH CARDIOVASCULAR DISEASES, METHODS OF DETECTION AND USES THEREOF | CELERA CORP (US) | 2021-06-03 | — | — | US | disclosed |
| EP-3185782-B1 | DEVICE FOR OBTAINING BIOLOGICAL MATERIAL AND/OR BIOLOGICAL INFORMATION FROM A SAMPLE WITH A HETEROGENEOUS MATRIX | BIOMERIEUX SA (FR) | 2021-06-02 | — | — | EP | disclosed |
| US-11008618-B2 | Genetic polymorphisms associated with autoinflammatory diseases, methods of detection and uses thereof | Celera Corporation (US) | 2021-05-18 | — | — | US | disclosed |
| US-10991450-B2 | Materials and methods for determining metabolizer status in humans | OHIO STATE INNOVATION FOUNDATION (US) | 2021-04-27 | — | — | US | disclosed |
| US-10988809-B2 | Genetic polymorphisms associated with coronary events and drug response, methods of detection and uses thereof | Celera Corporation (US) | 2021-04-27 | — | — | US | disclosed |
| US-10982281-B2 | Genetic polymorphisms associated with cardiovascular disorders and drug response, methods of detection and uses thereof | Celera Corporation (US) | 2021-04-20 | — | — | US | disclosed |
| CN-112553289-A | Method for evaluating effectiveness of CAR-T cells | 深圳市第二人民医院(深圳市转化医学研究院) | 2021-03-26 | — | — | CN | disclosed |
| US-10954565-B2 | Genetic polymorphisms associated with psoriasis, methods of detection and uses thereof | Celera Corporation (US) | 2021-03-23 | — | — | US | disclosed |
| CN-107326005-B | Dermis construction method without exogenous scaffold and culture solution | 广东博溪生物科技有限公司 | 2021-03-19 | — | — | CN | disclosed |
| US-10920276-B2 | Genetic polymorphisms associated with psoriasis, methods of detection and uses thereof | Celera Corporation (US) | 2021-02-16 | — | — | US | disclosed |
| CN-112342186-A | Culture method of hair follicle stem cells | 华科同济干细胞基因工程有限公司 | 2021-02-09 | — | — | CN | disclosed |
| CN-112300982-A | Hair follicle microarray co-culture system and application thereof in medicine for treating pathological alopecia | 华科同济干细胞基因工程有限公司 | 2021-02-02 | — | — | CN | disclosed |
| US-20210025000-A1 | GENETIC POLYMORPHISMS ASSOCIATED WITH LIVER FIBROSIS, METHODS OF DETECTION AND USES THEREOF | CELERA CORP (US) | 2021-01-28 | — | — | US | disclosed |
| CN-112263673-A | External medicine for promoting hair regeneration and preparation method thereof | 华科同济干细胞基因工程有限公司 | 2021-01-26 | — | — | CN | disclosed |
| US-10856854-B2 | Device for obtaining biological material and/or biological information from a sample with a heterogeneous matrix | BIOMERIEUX (FR) | 2020-12-08 | — | — | US | disclosed |
| US-20200377950-A1 | GENETIC POLYMORPHISMS ASSOCIATED WITH STROKE, METHODS OF DETECTION AND USES THEREOF | CELERA CORP (US) | 2020-12-03 | — | — | US | disclosed |
| WO-2020219572-A1 | USE OF BIOMARKERS FOR DEGENERATIVE DISC DISEASE | PREDICTIVE TECHNOLOGY GROUP, INC. (US) | 2020-10-29 | — | — | WO | disclosed |
| US-20200318197-A1 | Gene Expression Signatures for Detection of Underlying Philadelphia Chromosome-like (Ph-like) Events and Therapeutic Targeting in Leukemia | STC UNM (US) | 2020-10-08 | — | — | US | disclosed |
| EP-2346532-B1 | TARGETING CONSTRUCT COMPRISING ANTI-POLYMER ANTIBODY AND MICROVESICLES BINDING TO THE SAME | BRACCO SUISSE SA (CH) | 2020-10-07 | — | — | EP | disclosed |
| WO-2020196474-A1 | ANTIBODY-PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE | 第一三共株式会社 | 2020-10-01 | — | — | WO | disclosed |
| US-20200270689-A1 | GENETIC POLYMORPHISMS ASSOCIATED WITH STATIN RESPONSE AND CARDIOVASCULAR DISEASES, METHODS OF DETECTION AND USES THEREOF | CELERA CORP (US) | 2020-08-27 | — | — | US | disclosed |
| US-20200270688-A1 | GENETIC POLYMORPHISMS ASSOCIATED WITH MYOCARDIAL INFARCTION, METHODS OF DETECTION AND USES THEREOF | CELERA CORP (US) | 2020-08-27 | — | — | US | disclosed |
| US-10718023-B2 | Genetic polymorphisms associated with liver fibrosis, methods of detection and uses thereof | Celera Corporation (US) | 2020-07-21 | — | — | US | disclosed |
| CN-108375635-B | Method for detecting enramycin residue in animal tissue | 中国农业大学 | 2020-07-14 | — | — | CN | disclosed |
| US-20200206331-A1 | AN IMMUNOGENIC COMPOSITION HAVING IMPROVED STABILITY, ENHANCED IMMUNOGENICITY AND REDUCED REACTOGENICITY AND PROCESS FOR PREPARATION THEREOF | SERUM INSTITUTE OF INDIA PVT LTD (IN) | 2020-07-02 | — | — | US | disclosed |
| EP-3660508-A1 | GENETIC POLYMORPHISMS ASSOCIATED WITH STATIN RESPONSE AND CARDIOVASCULAR DISEASES | Celera Corporation (US) | 2020-06-03 | — | — | EP | disclosed |
| EP-3655024-A1 | AN IMMUNOGENIC COMPOSITION HAVING IMPROVED STABILITY, ENHANCED IMMUNOGENICITY AND REDUCED REACTOGENICITY AND PROCESS FOR PREPARATION THEREOF | Serum Institute of India Private Limited (IN) | 2020-05-27 | — | — | EP | disclosed |
| CN-111154719-A | Method for preparing mature red blood cells in vitro by using peripheral blood and preparation | 西湖生物医药科技(杭州)有限公司 | 2020-05-15 | — | — | CN | disclosed |
| EP-3495500-B1 | GENETIC POLYMORPHISMS ASSOCIATED WITH VENOUS THROMBOSIS AND STATIN RESPONSE, METHODS OF DETECTION AND USES THEREOF | CELERA CORP (US) | 2020-05-13 | — | — | EP | disclosed |
| EP-3643792-A1 | DETECTION AND ANALYSIS OF SEQUENCE VARIATIONS IN A TARGET NUCLEIC ACID | Fujirebio Europe N.V. (BE) | 2020-04-29 | — | — | EP | disclosed |
| US-20200123610-A1 | GENETIC POLYMORPHISMS ASSOCIATED WITH CORONARY EVENTS AND DRUG RESPONSE, METHODS OF DETECTION AND USES THEREOF | CELERA CORP (US) | 2020-04-23 | — | — | US | disclosed |
| US-10626453-B2 | Portable nucleic acid analysis system and high-performance microfluidic electroactive polymer actuators | SRI INTERNATIONAL (US) | 2020-04-21 | — | — | US | disclosed |
| CN-111032078-A | Immunogenic compositions with improved stability, enhanced immunogenicity and reduced reactogenicity and methods of making the same | 血清研究所印度私人有限公司 | 2020-04-17 | — | — | CN | disclosed |
| US-20200085940-A1 | METHODS FOR ENTEROVIRUS INACTIVATION, ADJUVANT ADSORPTION AND DOSE REDUCED VACCINE COMPOSITIONS OBTAINED THEREOF | SERUM INSTITUTE OF INDIA PVT LTD. (IN) | 2020-03-19 | — | — | US | disclosed |
| US-20200087728-A1 | GENETIC MARKERS ASSOCIATED WITH ENDOMETRIOSIS AND USE THEREOF | JUNEAU BIOSCIENCES, L.L.C. | 2020-03-19 | — | — | US | disclosed |
| US-10584384-B2 | Genetic polymorphisms associated with cardiovascular diseases, methods of detection and uses thereof | Celera Corporation (US) | 2020-03-10 | — | — | US | disclosed |
| US-10563263-B2 | Genetic polymorphisms associated with statin response and cardiovascular diseases, methods of detection and uses thereof | Celera Corporation (US) | 2020-02-18 | — | — | US | disclosed |
| US-10550434-B2 | Genetic polymorphisms associated with myocardial infarction, methods of detection and uses thereof | Celera Corporation (US) | 2020-02-04 | — | — | US | disclosed |
| EP-3396376-B1 | GENETIC POLYMORPHISMS ASSOCIATED WITH STATIN RESPONSE AND CARDIOVASCULAR DISEASES | CELERA CORP (US) | 2020-01-29 | — | — | EP | disclosed |
| CN-109652369-B | Method for preparing mature red blood cells in vitro by using peripheral blood and preparation | 西湖生物医药科技(杭州)有限公司 | 2020-01-03 | — | — | CN | disclosed |
| CN-110354303-A | A kind of antibacterial method of modifying of metallic titanium surface | 北京化工大学 | 2019-10-22 | — | — | CN | disclosed |
| US-10435749-B2 | Genetic polymorphisms associated with coronary events and drug response, methods of detection and uses thereof | Celera Corporation (US) | 2019-10-08 | — | — | US | disclosed |
| US-20190300958-A1 | GENETIC POLYMORPHISMS ASSOCIATED WITH VENOUS THROMBOSIS AND STATIN RESPONSE, METHODS OF DETECTION AND USES THEREOF | CELERA CORP (US) | 2019-10-03 | — | — | US | disclosed |
| US-20190292598-A1 | GENETIC POLYMORPHISMS ASSOCIATED WITH CARDIOVASCULAR DISORDERS AND DRUG RESPONSE, METHODS OF DETECTION AND USES THEREOF | CELERA CORP (US) | 2019-09-26 | — | — | US | disclosed |
| US-20190249253-A1 | GENETIC POLYMORPHISMS ASSOCIATED WITH VENOUS THROMBOSIS, METHODS OF DETECTION AND USES THEREOF | CELERA CORP (US) | 2019-08-15 | — | — | US | disclosed |
| CN-106566813-B | Hybridoma cell strain XA272-918, antibody and its application | 中国人民解放军第四军医大学 | 2019-07-26 | — | — | CN | disclosed |
| US-20190226026-A1 | GENETIC POLYMORPHISMS ASSOCIATED WITH PSORIASIS, METHODS OF DETECTION AND USES THEREOF | CELERA CORP (US) | 2019-07-25 | — | — | US | disclosed |
| CN-106544323-B | Hybridoma cell strain XA272-907, antibody and its application | 中国人民解放军第四军医大学 | 2019-06-25 | — | — | CN | disclosed |
| EP-3495500-A1 | GENETIC POLYMORPHISMS ASSOCIATED WITH VENOUS THROMBOSIS AND STATIN RESPONSE, METHODS OF DETECTION AND USES THEREOF | Celera Corporation (US) | 2019-06-12 | — | — | EP | disclosed |
| CN-106566812-B | Hybridoma cell strain XA272-917, antibody and its application | 中国人民解放军第四军医大学 | 2019-06-04 | — | — | CN | disclosed |
| US-10301679-B2 | Genetic polymorphisms, associated with rheumatoid arthritis, methods of detection and uses thereof | Celera Corporation (US) | 2019-05-28 | — | — | US | disclosed |
| US-20190136326-A1 | MOLECULAR PROGNOSTIC SIGNATURE FOR PREDICTING BREAST CANCER METASTASIS, AND USES THEREOF | CELERA CORP (US) | 2019-05-09 | — | — | US | disclosed |
| US-20190127796-A1 | GENETIC POLYMORPHISMS ASSOCIATED WITH LIVER FIBROSIS, METHODS OF DETECTION AND USES THEREOF | CELERA CORP (US) | 2019-05-02 | — | — | US | disclosed |
| EP-2635709-B1 | GENETIC POLYMORPHISMS ASSOCIATED WITH VENOUS THROMBOSIS AND STATIN RESPONSE, METHODS OF DETECTION AND USES THEREOF | CELERA CORP (US) | 2019-05-01 | — | — | EP | disclosed |
| CN-109652369-A | Method for preparing mature red blood cells in vitro by using peripheral blood and preparation | 西湖生物医药科技(杭州)有限公司 | 2019-04-19 | — | — | CN | disclosed |
| CN-109381487-A | Application of the human umbilical cord mesenchymal stem cells in preparation prevention and/or treatment osteoarthritis drugs | 天津长和生物技术有限公司 | 2019-02-26 | — | — | CN | disclosed |
| US-20190050527-A1 | Materials and Methods for Determining Metabolizer Status in Humans | OHIO STATE INNOVATION FOUNDATION | 2019-02-14 | — | — | US | disclosed |
| US-20190040105-A1 | Method for Preventing and Treating Hyperpermeability | APEPTICO FORSCHUNG UND ENTWICKLUNG GMBH (AT) | 2019-02-07 | — | — | US | disclosed |
| US-20190032136-A1 | GENETIC POLYMORPHISMS ASSOCIATED WITH STATIN RESPONSE AND CARDIOVASCULAR DISEASES, METHODS OF DETECTION AND USES THEREOF | CELERA CORP (US) | 2019-01-31 | — | — | US | disclosed |
| US-20190024174-A1 | GENETIC POLYMORPHISMS ASSOCIATED WITH PSORIASIS, METHODS OF DETECTION AND USES THEREOF | CELERA CORP (US) | 2019-01-24 | — | — | US | disclosed |
| WO-2019016654-A1 | AN IMMUNOGENIC COMPOSITION HAVING IMPROVED STABILITY, ENHANCED IMMUNOGENICITY AND REDUCED REACTOGENICITY AND PROCESS FOR PREPARATION THEREOF | SERUM INSTITUTE OF INDIA PVT LTD. (IN) | 2019-01-24 | — | — | WO | disclosed |
| US-10131949-B2 | Genetic polymorphisms associated with psoriasis, methods of detection and uses thereof | Celera Corporation (US) | 2018-11-20 | — | — | US | disclosed |
| CN-108753946-A | Method and composition for identifying and treating lupus | 健泰科生物技术公司 | 2018-11-06 | — | — | CN | disclosed |
| US-20180312923-A1 | GENETIC POLYMORPHISMS ASSOCIATED WITH STROKE, METHODS OF DETECTION AND USES THEREOF | CELERA CORP (US) | 2018-11-01 | — | — | US | disclosed |
| EP-3396376-A1 | GENETIC POLYMORPHISMS ASSOCIATED WITH STATIN RESPONSE AND CARDIOVASCULAR DISEASES, METHODS OF DETECTION AND USES THEREOF | Celera Corporation (US) | 2018-10-31 | — | — | EP | disclosed |
| US-10113198-B2 | Genetic polymorphisms associated with rheumatoid arthritis, methods of detection and uses thereof | Celera Corporation (US) | 2018-10-30 | — | — | US | disclosed |
| US-20180305762-A1 | GENETIC POLYMORPHISMS ASSOCIATED WITH CARDIOVASCULAR DISORDERS AND DRUG RESPONSE, METHODS OF DETECTION AND USES THEREOF | CELERA CORP (US) | 2018-10-25 | — | — | US | disclosed |
| CN-108699130-A | Recombination chimeric protein for selectin targeting | 博莱科瑞士股份有限公司 | 2018-10-23 | — | — | CN | disclosed |
| US-20180251842-A1 | GENETIC POLYMORPHISMS ASSOCIATED WITH MYOCARDIAL INFARCTION, METHODS OF DETECTION AND USES THEREOF | CELERA CORP (US) | 2018-09-06 | — | — | US | disclosed |
| CN-108375635-A | A kind of remaining method of enramycin in detection animal tissue | 中国农业大学 | 2018-08-07 | — | — | CN | disclosed |
| EP-2222404-B1 | PROTEASE DETECTION | MOLOGIC LTD (GB) | 2018-08-01 | — | — | EP | disclosed |
| CN-108285893-A | The monoclonal antibody of hybridoma cell strain and anti-human CTRP3b and its application | 中国人民解放军第四军医大学 | 2018-07-17 | — | — | CN | disclosed |
| US-10006088-B2 | Genetic polymorphisms associated with psoriasis, methods of detection and uses thereof | Celera Corporation (US) | 2018-06-26 | — | — | US | disclosed |
| US-20180171407-A1 | GENETIC POLYMORPHISMS ASSOCIATED WITH AUTOINFLAMMATORY DISEASES, METHODS OF DETECTION AND USES THEREOF | CELERA CORP (US) | 2018-06-21 | — | — | US | disclosed |
| CN-104593488-B | For identifying and treating the method and composition of lupus | 健泰科生物技术公司 | 2018-06-12 | — | — | CN | disclosed |
| EP-3048175-B1 | GENETIC POLYMORPHISM ASSOCIATED WITH STROKE, THERAPY BASED ON THE DETECTION OF THE POLYMORPHISM AND USE OF KITS CONTAINING REAGENTS FOR DETECTING THE POLYMORPHISM | CELERA CORP (US) | 2018-05-16 | — | — | EP | disclosed |
| EP-3318643-A2 | METHODS AND COMPOSITIONS FOR IDENTIFYING AND TREATING LUPUS | Genentech, Inc. (US) | 2018-05-09 | — | — | EP | disclosed |
| EP-3093351-B1 | GENETIC POLYMORPHISMS ASSOCIATED WITH CARDIOVASCULAR DISEASES, METHODS OF DETECTION AND USES THEREOF | CELERA CORP (US) | 2018-04-18 | — | — | EP | disclosed |
| US-9938576-B1 | Materials and methods for determining metabolizer status in humans | OHIO STATE INNOVATION FOUNDATION (US) | 2018-04-10 | — | — | US | disclosed |
| CN-107880100-A | High-affinity SIRP α reagents | 小利兰·斯坦福大学托管委员会 | 2018-04-06 | — | — | CN | disclosed |
| CN-107873732-A | The preparation method of one plant growth regulators | 常州市鑫嘉生物科技有限公司 | 2018-04-06 | — | — | CN | disclosed |
| US-9932637-B2 | Genetic polymorphisms associated with cardiovascular disorders and drug response, methods of detection and uses thereof | Celera Corporation (US) | 2018-04-03 | — | — | US | disclosed |
| EP-3056899-B1 | GENETIC POLYMORPHISMS ASSOCIATED WITH STATIN RESPONSE AND CARDIOVASCULAR DISEASES, METHODS OF DETECTION AND USES THEREOF | CELERA CORP (US) | 2018-03-28 | — | — | EP | disclosed |
| US-20180080083-A1 | Methods for Detecting an increased risk for coronary heart disease | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2018-03-22 | — | — | US | disclosed |
| US-20180073075-A1 | Risk Factors of Cigarette Smoke-Induced Spriometric Phenotypes | SILICON VALLEY BANK | 2018-03-15 | — | — | US | disclosed |
| CN-104136037-B | high affinity SIRP-alpha reagents | 小利兰·斯坦福大学托管委员会 | 2018-02-23 | — | — | CN | disclosed |
| EP-2612924-B1 | METHODS AND COMPOSITIONS FOR IDENTIFYING AND TREATING LUPUS | GENENTECH INC (US) | 2017-12-20 | — | — | EP | disclosed |
| US-20170298449-A1 | GENE EXPRESSION SIGNATURES FOR DETECTION OF UNDERLYING PHILADELPHIA CHROMOSOME-LIKE (PH-LIKE) EVENTS AND THERAPEUTIC TARGETING IN LEUKEMIA | CHILDREN'S ONCOLOGY GROUP | 2017-10-19 | — | — | US | disclosed |
| US-20170292159-A1 | GENETIC POLYMORPHISMS ASSOCIATED WITH CARDIOVASCULAR DISEASES, METHODS OF DETECTION AND USES THEREOF | CELERA CORP (US) | 2017-10-12 | — | — | US | disclosed |
| CN-107213469-A | Monomethyl valine compound that can be with ligand coupling | 西雅图基因公司 | 2017-09-29 | — | — | CN | disclosed |
| US-20170273670-A1 | Device for Obtaining Biological Material and/or Biological Information from a Sample with a Heterogeneous Matrix | BIOMERIEUX (FR) | 2017-09-28 | — | — | US | disclosed |
| EP-2592157-B1 | GENETIC POLYMORPHISMS ASSOCIATED WITH CORONARY EVENTS AND DRUG RESPONSE, METHODS OF DETECTION AND USES THEREOF | CELERA CORP (US) | 2017-08-16 | — | — | EP | disclosed |
| CN-103394083-B | Monomethyl valine compound that can be with ligand coupling | 西雅图基因公司 | 2017-07-18 | — | — | CN | disclosed |
| CN-105307695-B | With antithrombotic/sterilization S nitroso N acetyl penicilliamines (SNAP) the doping nitric oxide releasing polymer for improving stability | 密执安大学评议会 | 2017-07-18 | — | — | CN | disclosed |
| EP-3185782-A1 | DEVICE FOR OBTAINING BIOLOGICAL MATERIAL AND/OR BIOLOGICAL INFORMATION FROM A SAMPLE WITH A HETEROGENEOUS MATRIX | Biomérieux (FR) | 2017-07-05 | — | — | EP | disclosed |
| US-20170145503-A1 | GENETIC POLYMORPHISMS ASSOCIATED WITH RHEUMATOID ARTHRITIS, METODS OF DETECTION AND USES THEREOF | Celera Corporation (US) | 2017-05-25 | — | — | US | disclosed |
| CN-106636005-A | Hybridoma cell strain XA272-919, antibody and applications of antibody | 中国人民解放军第四军医大学 | 2017-05-10 | — | — | CN | disclosed |
| US-9631240-B2 | Genetic variations associated with tumors | GENENTECH, INC. (US) | 2017-04-25 | — | — | US | disclosed |
| EP-2089540-B1 | GENETIC VARIATIONS ASSOCIATED WITH TUMORS | GENENTECH INC (US) | 2017-04-19 | — | — | EP | disclosed |
| CN-106566813-A | Hybridoma cell strain XA272-918, antibody and applications of antibody | 中国人民解放军第四军医大学 | 2017-04-19 | — | — | CN | disclosed |
| CN-106566812-A | Hybridoma cell strain XA272-917, antibody and application of antibody | 中国人民解放军第四军医大学 | 2017-04-19 | — | — | CN | disclosed |
| EP-2764116-B1 | GENETIC POLYMORPHISMS ASSOCIATED WITH VENOUS THROMBOSIS IN WOMEN, METHODS OF DETECTION AND USES THEREOF | ZOTZ RAINER BERND (DE) | 2017-03-29 | — | — | EP | disclosed |
| CN-106544323-A | Hybridoma cell strain XA272 907, antibody and its application | 中国人民解放军第四军医大学 | 2017-03-29 | — | — | CN | disclosed |
| US-20170058324-A1 | PORTABLE NUCLEIC ACID ANALYSIS SYSTEM AND HIGH-PERFORMANCE MICROFLUIDIC ELECTROACTIVE POLYMER ACTUATORS | STANFORD RES INST INT (US) | 2017-03-02 | — | — | US | disclosed |
| EP-3132069-A1 | PORTABLE NUCLEIC ACID ANALYSIS SYSTEM AND HIGH-PERFORMANCE MICROFLUIDIC ELECTROACTIVE POLYMER ACTUATORS | SRI International Inc. (US) | 2017-02-22 | — | — | EP | disclosed |
| EP-3132073-A1 | PORTABLE NUCLEIC ACID ANALYSIS SYSTEM AND HIGH-PERFORMANCE MICROFLUIDIC ELECTROACTIVE POLYMER ACTUATORS | SRI International (US) | 2017-02-22 | — | — | EP | disclosed |
| CN-106399235-A | Method for isolating human umbilical cord mesenchymal stem cells | 浙江译美生物科技有限公司 | 2017-02-15 | — | — | CN | disclosed |
| US-20170029888-A1 | GENETIC POLYMORPHISMS ASSOCIATED WITH CARDIOVASCULAR DISORDERS AND DRUG RESPONSE, METHODS OF DETECTION AND USES THEREOF | CELERA CORP (US) | 2017-02-02 | — | — | US | disclosed |
| US-20170029889-A1 | GENETIC POLYMORPHISMS ASSOCIATED WITH RHEUMATOID ARTHRITIS, METHODS OF DETECTION AND USES THEREOF | CELERA CORP (US) | 2017-02-02 | — | — | US | disclosed |
| US-20170030859-A1 | PORTABLE NUCLEIC ACID ANALYSIS SYSTEM AND HIGH-PERFORMANCE MICROFLUIDIC ELECTROACTIVE POLYMER ACTUATORS | SRI INTERNATIONAL | 2017-02-02 | — | — | US | disclosed |
| US-20170022564-A1 | GENETIC POLYMORPHISMS ASSOCIATED WITH PSORIASIS, METHODS OF DETECTION AND USES THEREOF | CELERA CORP (US) | 2017-01-26 | — | — | US | disclosed |
| US-20170022563-A1 | GENETIC POLYMORPHISMS ASSOCIATED WITH CORONARY EVENTS AND DRUG RESPONSE, METHODS OF DETECTION AND USES THEREOF | CELERA CORP (US) | 2017-01-26 | — | — | US | disclosed |
| EP-3093351-A1 | GENETIC POLYMORPHISMS ASSOCIATED WITH CARDIOVASCULAR DISEASES, METHODS OF DETECTION AND USES THEREOF | Celera Corporation (US) | 2016-11-16 | — | — | EP | disclosed |
| US-20160319352-A1 | GENETIC POLYMORPHISMS ASSOCIATED WITH MYOCARDIAL INFARCTION, METHODS OF DETECTION AND USES THEREOF | CELERA CORP (US) | 2016-11-03 | — | — | US | disclosed |
| US-20160289766-A1 | MOLECULAR PROGNOSTIC SIGNATURE FOR PREDICTING BREAST CANCER METASTASIS, AND USES THEREOF | CELERA CORP (US) | 2016-10-06 | — | — | US | disclosed |
| US-20160281164-A1 | GENETIC POLYMORPHISMS ASSOCIATED WITH VENOUS THROMBOSIS, METHODS OF DETECTION AND USES THEREOF | CELERA CORP (US) | 2016-09-29 | — | — | US | disclosed |
| EP-2527472-B1 | A genetic lesion associated with cancer | UNIV YALE (US) | 2016-09-28 | — | — | EP | disclosed |
| US-20160265055-A1 | GENETIC POLYMORPHISMS ASSOCIATED WITH CARDIOVASCULAR DISORDERS AND DRUG RESPONSE, METHODS OF DETECTION AND USES THEREOF | CELERA CORP (US) | 2016-09-15 | — | — | US | disclosed |
| US-20160244836-A1 | GENETIC POLYMORPHISMS ASSOCIATED WITH PSORIASIS, METHODS OF DETECTION AND USES THEREOF | CELERA CORP (US) | 2016-08-25 | — | — | US | disclosed |
| US-20160244837-A1 | GENETIC POLYMORPHISMS ASSOCIATED WITH VENOUS THROMBOSIS AND STATIN RESPONSE, METHODS OF DETECTION AND USES THEREOF | CELERA CORP (US) | 2016-08-25 | — | — | US | disclosed |
| EP-3056899-A1 | GENETIC POLYMORPHISMS ASSOCIATED WITH STATIN RESPONSE AND CARDIOVASCULAR DISEASES, METHODS OF DETECTION AND USES THEREOF | Celera Corporation (US) | 2016-08-17 | — | — | EP | disclosed |
| US-20160222450-A1 | GENETIC POLYMORPHISMS ASSOCIATED WITH AUTOINFLAMMATORY DISEASES, METHODS OF DETECTION AND USES THEREOF | CELERA CORP (US) | 2016-08-04 | — | — | US | disclosed |
| EP-3048175-A1 | GENETIC POLYMORPHISM ASSOCIATED WITH STROKE, THERAPY BASED ON THE DETECTION OF THE POLYMORPHISM AND USE OF KITS CONTAINING REAGENTS FOR DETECTING THE POLYMORPHISM | Celera Corporation (US) | 2016-07-27 | — | — | EP | disclosed |
| US-9376706-B2 | Protease detection | MOLOGIC LIMITED (GB) | 2016-06-28 | — | — | US | disclosed |
| US-9371565-B2 | Genetic polymorphisms associated with psoriasis, methods of detection and uses thereof | Celera Corporation (US) | 2016-06-21 | — | — | US | disclosed |
| US-20160168639-A1 | GENETIC POLYMORPHISMS ASSOCIATED WITH STROKE, METHODS OF DETECTION AND USES THEREOF | CELERA CORP (US) | 2016-06-16 | — | — | US | disclosed |
| EP-2878680-B1 | Genetic polymorphisms associated with cardiovascular diseases, methods of detection and uses thereof | CELERA CORP (US) | 2016-06-08 | — | — | EP | disclosed |
| EP-2276855-B1 | GENETIC POLYMORPHISMS ASSOCIATED WIITH VENOUS THROMBOSIS, METHODS OF DETECTION AND USES THEREOF | CELERA CORP (US) | 2016-05-11 | — | — | EP | disclosed |
| EP-2474630-B1 | Genetic polymorphisms associated with myocardial infarction, methods of detection and uses thereof | CELERA CORP (US) | 2016-04-27 | — | — | EP | disclosed |
| US-20160108473-A1 | GENETIC POLYMORPHISMS ASSOCIATED WITH STATIN RESPONSE AND CARDIOVASCULAR DISEASES, METHODS OF DETECTION AND USES THEREOF | CELERA CORP (US) | 2016-04-21 | — | — | US | disclosed |
| EP-2322669-B1 | Method for typing and detecting HBV | FUJIREBIO EUROP N V (BE) | 2016-04-06 | — | — | EP | disclosed |
| EP-2561352-B1 | GENETIC POLYMORPHISMS ASSOCIATED WITH STATIN RESPONSE AND CARDIOVASCULAR DISEASES, METHODS OF DETECTION AND USES THEREOF | CELERA CORP (US) | 2016-03-30 | — | — | EP | disclosed |
| WO-2016030642-A1 | DEVICE FOR OBTAINING BIOLOGICAL MATERIAL AND/OR BIOLOGICAL INFORMATION FROM A SAMPLE WITH A HETEROGENEOUS MATRIX | bioMérieux (FR) | 2016-03-03 | — | — | WO | disclosed |
| US-20160053322-A1 | GENETIC MARKERS ASSOCIATED WITH SCOLIOSIS AND USES THEREOF | Schwegman, Lundberg & Woessner, P.A. | 2016-02-25 | — | — | US | disclosed |
| US-20160046991-A1 | GENETIC POLYMORPHISMS ASSOCIATED WITH LIVER FIBROSIS, METHODS OF DETECTION AND USES THEREOF | Celera Corporation (US) | 2016-02-18 | — | — | US | disclosed |
| EP-2186913-B1 | Genetic polymorphisms associated with cardiovascular disorders and drug response, methods of detection and uses thereof | CELERA CORP (US) | 2016-02-10 | — | — | EP | disclosed |
| US-20160032388-A1 | GENETIC POLYMORPHISMS ASSOCIATED WITH LIVER FIBROSIS, METHODS OF DETECTION AND USES THEREOF | CELERA CORP (US) | 2016-02-04 | — | — | US | disclosed |
| CN-105307695-A | Thromboresistant/bactericidal s-nitroso-n-acetylpenicillamine (snap)-doped nitric oxide release polymers with enhanced stability | UNIV MICHIGAN | 2016-02-03 | — | — | CN | disclosed |
| EP-2971108-A1 | PREDICTING RESPONSE TO EGFR INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2016-01-20 | — | — | EP | disclosed |
| US-20150361494-A1 | Genetic Markers Associated with Endometriosis and Use Thereof | JUNEAU BIOSCIENCES, LLC (US) | 2015-12-17 | — | — | US | disclosed |
| EP-2500440-B1 | Genetic polymorphisms associated with myocardial infarction, methods of detection and uses thereof | CELERA CORP (US) | 2015-12-16 | — | — | EP | disclosed |
| EP-2257298-B1 | GENETIC POLYMORPHISM ASSOCIATED WITH STROKE, THERAPY BASED ON THE DETECTION OF THE POLYMORPHISM AND USE OF KITS CONTAINING REAGENTS FOR DETECTING THE POLYMORPHISM | CELERA CORP (US) | 2015-12-02 | — | — | EP | disclosed |
| US-20150337373-A1 | Genetic Markers Associated with Degenerative Disc Disease and Uses Thereof | AXIAL BIOTECH, INC. (US) | 2015-11-26 | — | — | US | disclosed |
| EP-2471952-B1 | Genetic polymorphisms associated with cardiovascular disorders and drug response, methods of detection and uses thereof | CELERA CORP (US) | 2015-11-11 | — | — | EP | disclosed |
| CN-104998273-A | Monomethylvaline compounds capable of coupling to ligands | SEATTLE GENETICS INC | 2015-10-28 | — | — | CN | disclosed |
| WO-2015160864-A1 | PORTABLE NUCLEIC ACID ANALYSIS SYSTEM AND HIGH-PERFORMANCE MICROFLUIDIC ELECTROACTIVE POLYMER ACTUATORS | SRI INTERNATIONAL (US) | 2015-10-22 | — | — | WO | disclosed |
| WO-2015160863-A1 | PORTABLE NUCLEIC ACID ANALYSIS SYSTEMAND HIGH-PERFORMANCE MICROFLUIDIC ELECTROACTIVE POLYMER ACTUATORS | SRI INTERNATIONAL (US) | 2015-10-22 | — | — | WO | disclosed |
| US-9157885-B2 | Method of electrochemically detecting target substance, method of electrochemically detecting analyte, test chip, and detection set | SYSMEX CORPORATION (JP) | 2015-10-13 | — | — | US | disclosed |
| US-20150259744-A1 | GENETIC POLYMORPHISMS ASSOCIATED WITH PSORIASIS, METHODS OF DETECTION AND USES THEREOF | CELERA CORP (US) | 2015-09-17 | — | — | US | disclosed |
| US-20150259752-A1 | Genetic Lesion Associated With Cancer | UNIV YALE (US) | 2015-09-17 | — | — | US | disclosed |
| EP-2474632-B1 | Genetic polymorphisms associated with myocardial infarction, methods of detection and uses thereof | CELERA CORP (US) | 2015-08-12 | — | — | EP | disclosed |
| EP-2639319-B1 | Genetic polymorphisms associated with Psoriasis, methods of detection and uses thereof | CELERA CORP (US) | 2015-07-08 | — | — | EP | disclosed |
| US-20150158939-A1 | Methods and Compositions for the Treatment of Immune Disorders | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-06-11 | — | — | US | disclosed |
| US-20150152471-A1 | PROTEASE DETECTION | MOLOGIC LIMITED (GB) | 2015-06-04 | — | — | US | disclosed |
| EP-2878680-A1 | Genetic polymorphisms associated with cardiovascular diseases, methods of detection and uses thereof | Celera Corporation (US) | 2015-06-03 | — | — | EP | disclosed |
| US-20150111775-A1 | GENETIC POLYMORPHISMS ASSOCIATED WITH CARDIOVASCULAR DISORDERS AND DRUG RESPONSE, METHODS OF DETECTION AND USES THEREOF | CELERA CORP (US) | 2015-04-23 | — | — | US | disclosed |
| EP-2639318-B1 | Genetic polymorphisms associated with Psoriasis, methods of detection and uses thereof | CELERA CORP (US) | 2015-04-08 | — | — | EP | disclosed |
| CN-104507967-A | Anti-cxcr3 antibodies | GENZYME CORP | 2015-04-08 | — | — | CN | disclosed |
| CN-103627787-B | Probe kit for detecting target gene copy-number alteration in t(8;21) AML | HEMATOLOGY HOSPITAL CHINESE ACADEMY OF MEDICAL SCIENCES | 2015-04-08 | — | — | CN | disclosed |
| EP-2431483-B1 | Genetic polymorphisms associated with venous thrombosis, methods of detection and uses thereof | CELERA CORP (US) | 2015-04-01 | — | — | EP | disclosed |
| US-8993253-B2 | Protease detection | MOLOGIC LTD (GB) | 2015-03-31 | — | — | US | disclosed |
| CN-103555820-B | Four-color gene probe kit for detecting genes related to breast cancer G1/S phase regulation | INST OF HEMATOLOGY & BLOOD DISEASES HOSPITAL CAMS | 2015-03-11 | — | — | CN | disclosed |
| US-8975022-B2 | Genetic polymorphisms associated with psoriasis, methdos of detection and uses thereof | Celera Corporation (US) | 2015-03-10 | — | — | US | disclosed |
| EP-2639317-B1 | Genetic polymorphisms associated with psoriasis, methods of detection and uses thereof | CELERA CORP (US) | 2015-03-04 | — | — | EP | disclosed |
| EP-2636754-B1 | Genetic polymorphisms associated with psoriasis, methods of detection and uses thereof | CELERA CORP (US) | 2015-03-04 | — | — | EP | disclosed |
| US-20150025230-A1 | Single Nucleotide Polymorphisms in BRCA1 and Cancer Risk | YALE UNIVERSITY (US) | 2015-01-22 | — | — | US | disclosed |
| CN-104302660-A | Method for detecting an infection by the hepatitis c virus | BIO RAD INNOVATIONS | 2015-01-21 | — | — | CN | disclosed |
| US-20150010537-A1 | GENETIC VARIATIONS ASSOCIATED WITH TUMORS | GENENTECH, INC. (US) | 2015-01-08 | — | — | US | disclosed |
| EP-2602332-B1 | Genetic polymorphisms associated with liver fibrosis, methods of detection and uses thereof | CELERA CORP (US) | 2015-01-07 | — | — | EP | disclosed |
| EP-2520668-B1 | A molecular prognostic signature for predicting breast cancer distant metastasis, and uses thereof | CELERA CORP (US) | 2014-12-24 | — | — | EP | disclosed |
| US-20140364358-A1 | Method for Preventing and Treating Hyperpermeability | APEPTICO FORSCHUNG UND ENTWICKLUNG GMBH (AT) | 2014-12-11 | — | — | US | disclosed |
| US-20140322166-A1 | GENE EXPRESSION SIGNATURES FOR DETECTION OF UNDERLYING PHILADELPHIA CHROMOSOME-LIKE (PH-LIKE) EVENTS AND THERAPEUTIC TARGETING IN LEUKEMIA | STC. UNM (US) | 2014-10-30 | — | — | US | disclosed |
| US-8871205-B2 | Methods and compositions for the treatment of immune disorders | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2014-10-28 | — | — | US | disclosed |
| US-20140315844-A1 | MULTI-GENE SIGNATURES FOR PREDICTING RESPONSE TO CHEMOTHERAPY OR RISK OF METASTASIS FOR BREAST CANCER | Celera Corporation (US) | 2014-10-23 | — | — | US | disclosed |
| US-20140314747-A1 | PREDICTING RESPONSE TO EGFR INHIBITORS | GENENTECH, INC. (US) | 2014-10-23 | — | — | US | disclosed |
| US-20140309139-A1 | GENETIC POLYMORPHISMS ASSOCIATED WITH VENOUS THROMBOSIS IN WOMEN, METHODS OF DETECTION AND USES THEREOF | Zotz, Rainer Bernd (DE) | 2014-10-16 | — | — | US | disclosed |
| US-8859203-B2 | Method for typing and detecting HBV | FUJIREBIO EUROPE N.V. (BE) | 2014-10-14 | — | — | US | disclosed |
| WO-2014159638-A1 | PREDICTING RESPONSE TO EGFR INHIBITORS | GENENTECH, INC. (US) | 2014-10-02 | — | — | WO | disclosed |
| EP-2782586-A1 | IMPROVED SYNERGISTIC ANTI-DIABETIC COMPOSITIONS | Ozstar Therapeutics Pty Ltd (AU) | 2014-10-01 | — | — | EP | disclosed |
| US-20140271672-A1 | GENETIC POLYMORPHISMS ASSOCIATED WITH MYOCARDIAL INFARCTION, METHODS OF DETECTION AND USES THEREOF | Celera Corporation (US) | 2014-09-18 | — | — | US | disclosed |
| US-8835106-B2 | Method for typing and detecting HBV | FUJIREBIO EUROPE N.V. (BE) | 2014-09-16 | — | — | US | disclosed |
| US-20140256576-A1 | GENETIC POLYMORPHISMS ASSOCIATED WITH LIVER FIBROSIS, METHODS OF DETECTION AND USES THEREOF | Celera Corporation (US) | 2014-09-11 | — | — | US | disclosed |
| US-20140234291-A1 | GENETIC POLYMORPHISMS ASSOCIATED WITH RHEUMATOID ARTHRITIS, METHODS OF DETECTION AND USES THEREOF | Celera Corporation (US) | 2014-08-21 | — | — | US | disclosed |
| US-20140235605-A1 | GENETIC POLYMORPHISMS ASSOCIATED WITH STATIN RESPONSE AND CARDIOVASCULAR DISEASES, METHODS OF DETECTION AND USES THEREOF | Celera Corporation (US) | 2014-08-21 | — | — | US | disclosed |
| EP-2764116-A1 | GENETIC POLYMORPHISMS ASSOCIATED WITH VENOUS THROMBOSIS IN WOMEN, METHODS OF DETECTION AND USES THEREOF | Zotz, Rainer Bernd (DE) | 2014-08-13 | — | — | EP | disclosed |
| US-20140221484-A1 | GENETIC POLYMORPHISMS ASSOCIATED WITH CARDIOVASCULAR DISORDERS AND DRUG RESPONSE, METHODS OF DETECTION AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-08-07 | — | — | US | disclosed |
| US-20140206002-A1 | Methods of Diagnosing Breast Cancer | NATIONAL INSTITUTES OF HEALTH-DIRECTOR DEITR | 2014-07-24 | — | — | US | disclosed |
| US-20140206003-A1 | Genetic Lesion Associated with Cancer | YALE UNIVERSITY (US) | 2014-07-24 | — | — | US | disclosed |
| US-20140199290-A1 | GENETIC POLYMORPHISMS ASSOCIATED WITH ALZHEIMER'S DISEASE, METHODS OF DETECTION AND USES THEREOF | Celera Corporation (US) | 2014-07-17 | — | — | US | disclosed |
| US-20140186333-A1 | GENETIC POLYMORPHISMS ASSOCIATED WITH VENOUS THROMBOSIS, METHODS OF DETECTION AND USES THEREOF | Celera Corporation (US) | 2014-07-03 | — | — | US | disclosed |
| US-20140179548-A1 | MOLECULAR PROGNOSTIC SIGNATURE FOR PREDICTING BREAST CANCER METASTASIS, AND USES THEREOF | Celera Corporation (US) | 2014-06-26 | — | — | US | disclosed |
| WO-2014085653-A1 | MULTI-GENE SIGNATURES FOR PREDICTING RESPONSE TO CHEMOTHERAPY OR RISK OF METASTASIS FOR BREAST CANCER | Celera Corporation (US) | 2014-06-05 | — | — | WO | disclosed |
| EP-2733222-A1 | Genetic polymorphisms associated with cardiovascular diseases, methods of detection and uses thereof | Celera Corporation (US) | 2014-05-21 | — | — | EP | disclosed |
| US-20140134186-A1 | GENETIC POLYMORPHISMS ASSOCIATED WITH ALZHEIMER'S DISEASE, METHODS OF DETECTION AND USES THEREOF | Celera Corporation (US) | 2014-05-15 | — | — | US | disclosed |
| WO-2014071200-A1 | BETA BLOCKER RESPONDER STATUS ASSAYS AND RELATED MATERIALS AND METHODS | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2014-05-08 | — | — | WO | disclosed |
| US-20140128362-A1 | GENETIC POLYMORPHISMS ASSOCIATED WITH VENOUS THROMBOSIS AND STATIN RESPONSE, METHODS OF DETECTION AND USES THEREOF | Celera Corporation (US) | 2014-05-08 | — | — | US | disclosed |
| US-20140127213-A1 | GENETIC POLYMORPHISMS ASSOCIATED WITH AUTOINFLAMMATORY DISEASES, METHODS OF DETECTION AND USES THEREOF | Celera Corporation (US) | 2014-05-08 | — | — | US | disclosed |
| US-20140120533-A1 | GENETIC POLYMORPHISMS ASSOCIATED WITH CARDIOVASCULAR DISEASES, METHODS OF DETECTION AND USES THEREOF | Celera Corporation (US) | 2014-05-01 | — | — | US | disclosed |
| US-8697435-B2 | Integrated sample preparation and analyte detection | MBIO DIAGNOSTICS, INC. (US) | 2014-04-15 | — | — | US | disclosed |
| US-8680041-B2 | Genetic variations associated with tumors | GENENTECH, INC. (US) | 2014-03-25 | — | — | US | disclosed |
| EP-2471953-B1 | Genetic polymorphisms associated with cardiovascular disorders and drug response, methods of detection and uses thereof | CELERA CORP (US) | 2014-03-19 | — | — | EP | disclosed |
| CN-1938046-B | Monomethylvaline compounds capable of coupling to ligands | SEATTLE GENETICS INC | 2014-03-19 | — | — | CN | disclosed |
| US-20140072957-A1 | GENETIC POLYMORPHISMS ASSOCIATED WITH LIVER FIBROSIS, METHODS OF DETECTION AND USES THEREOF | Celera Corporation (US) | 2014-03-13 | — | — | US | disclosed |
| US-20140072550-A1 | GENETIC POLYMORPHISMS ASSOCIATED WITH CORONARY EVENTS AND DRUG RESPONSE, METHODS OF DETECTION AND USES THEREOF | Celera Corporation (US) | 2014-03-13 | — | — | US | disclosed |
| US-20140057797-A1 | Methods for Detecting an increased risk for coronary heart disease | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-02-27 | — | — | US | disclosed |
| EP-2310525-B1 | GENETIC POLYMORPHISMS ASSOCIATED WITH CARDIOVASCULAR DISEASES, METHODS OF DETECTION AND USES THEREOF | CELERA CORP (US) | 2014-02-26 | — | — | EP | disclosed |
| EP-2474631-B1 | Genetic polymorphisms associated with myocardial infarction, methods of detection and uses thereof | CELERA CORP (US) | 2014-02-12 | — | — | EP | disclosed |
| EP-2412827-B1 | Genetic polymorphism associated with liver fibrosis methods of detection and uses thereof | CELERA CORP (US) | 2014-01-22 | — | — | EP | disclosed |
| EP-2386659-B1 | Genetic polymorphisms associated with cardiovascular disorders and drug response, methods of detection and uses thereof | CELERA CORP (US) | 2014-01-15 | — | — | EP | disclosed |
| US-8614058-B2 | Molecular prognostic signature for predicting breast cancer metastasis, and uses thereof | Celera Corporation (US) | 2013-12-24 | — | — | US | disclosed |
| US-20130315894-A1 | GENETIC POLYMORPHISMS ASSOCIATED WITH RHEUMATOID ARTHRITIS, METODS OF DETECTION AND USES THEREOF | CELERA CORP (US) | 2013-11-28 | — | — | US | disclosed |
| US-20130310261-A1 | Simplified Method of Determining Predisposition to Scoliosis | SCHRAMM MICHAEL R (US) | 2013-11-21 | — | — | US | disclosed |
| CN-103394083-A | Monomethylvaline compounds capable of conjugation to ligands | SEATTLE GENETICS INC | 2013-11-20 | — | — | CN | disclosed |
| US-20130303558-A1 | GENETIC POLYMORPHISMS ASSOCIATED WITH STROKE, METHODS OF DETECTION AND USES THEREOF | CELERA CORP (US) | 2013-11-14 | — | — | US | disclosed |
| US-20130288913-A1 | METHOD OF DETERMINING PREDISPOSITION TO SCOLIOSIS | SCHRAMM MICHAEL R (US) | 2013-10-31 | — | — | US | disclosed |
| US-20130274195-A1 | GENETIC POLYMORPHISMS ASSOCIATED WITH VENOUS THROMBOSIS, METHODS OF DETECTION AND USES THEREOF | CELERA CORP (US) | 2013-10-17 | — | — | US | disclosed |
| US-8557525-B1 | Composite metastasis score with weighted coefficients for predicting breast cancer metastasis, and uses thereof | Celera Corporation (US) | 2013-10-15 | — | — | US | disclosed |
| US-20130261137-A1 | Methods, Compounds and Compositions Relating to Activating a Latent Virus | ULC BUSINESS PLC (GB) | 2013-10-03 | — | — | US | disclosed |
| EP-2639317-A2 | Genetic polymorphisms associated with psoriasis, methods of detection and uses thereof | Celera Corporation (US) | 2013-09-18 | — | — | EP | disclosed |
| EP-2639318-A2 | Genetic polymorphisms associated with Psoriasis, methods of detection and uses thereof | Celera Corporation (US) | 2013-09-18 | — | — | EP | disclosed |
| EP-2639319-A2 | Genetic polymorphisms associated with Psoriasis, methods of detection and uses thereof | Celera Corporation (US) | 2013-09-18 | — | — | EP | disclosed |
| US-20130237447-A1 | GENETIC MARKERS ASSOCIATED WITH SCOLIOSIS AND USES THEREOF | NELSON LESA M (US) | 2013-09-12 | — | — | US | disclosed |
| EP-2635709-A2 | GENETIC POLYMORPHISMS ASSOCIATED WITH VENOUS THROMBOSIS AND STATIN RESPONSE, METHODS OF DETECTION AND USES THEREOF | Celera Corporation (US) | 2013-09-11 | — | — | EP | disclosed |
| EP-2636754-A2 | Genetic polymorphisms associated with psoriasis, methods of detection and uses thereof | Celera Corporation (US) | 2013-09-11 | — | — | EP | disclosed |
| US-20130216551-A1 | GENETIC POLYMORPHISMS ASSOCIATED WITH PSORIASIS, METHDOS OF DETECTION AND USES THEREOF | Celera Corporation (US) | 2013-08-22 | — | — | US | disclosed |
| US-20130209486-A1 | GENETIC POLYMORPHISMS ASSOCIATED WITH PSORIASIS, METHODS OF DETECTION AND USES THEREOF | Celera Corporation (US) | 2013-08-15 | — | — | US | disclosed |
| CN-103239733-A | Integrin targeting drug loaded albumin nanoparticle formulation and its preparation method | UNIV FUDAN SHANGHAI CANCER CT | 2013-08-14 | — | — | CN | disclosed |
| EP-2616052-A1 | METHODS, COMPOUNDS AND COMPOSITIONS RELATING TO ACTIVATING A LATENT VIRUS | UCL Business PLC (GB) | 2013-07-24 | — | — | EP | disclosed |
| EP-0776970-B2 | Stable enzyme composition comprising a thermostable nucleic acid polymerase enzyme | HOFFMANN LA ROCHE (CH) | 2013-07-24 | — | — | EP | disclosed |
| EP-2612924-A2 | Methods and compositions for indentifying and treating lupus | Genentech, Inc. (US) | 2013-07-10 | — | — | EP | disclosed |
| WO-2013090419-A1 | GENE EXPRESSION SIGNATURES FOR DETECTION OF UNDERLYING PHILADELPHIA CHROMOSOME-LIKE (PH-LIKE) EVENTS AND THERAPEUTIC TARGETING IN LEUKEMIA | STC.UNM (US) | 2013-06-20 | — | — | WO | disclosed |
| US-20130150250-A1 | RISK FACTORS OF CIGARETTE SMOKE-INDUCED SPIROMETRIC PHENOTYPES | WEBB BRADLEY TODD (US) | 2013-06-13 | — | — | US | disclosed |
| EP-2602332-A1 | Genetic polymorphisms associated with liver fibrosis, methods of detection and uses thereof | Celera Corporation (US) | 2013-06-12 | — | — | EP | disclosed |
| WO-2013075172-A1 | IMPROVED SYNERGISTIC ANTI-DIABETIC COMPOSITIONS | OZSTAR THERAPEUTICS PTY LTD (AU) | 2013-05-30 | — | — | WO | disclosed |
| EP-2592157-A1 | Genetic polymorphisms associated with coronary events and drug response, methods of detection and uses thereof | Celera Corporation (US) | 2013-05-15 | — | — | EP | disclosed |
| EP-2386656-B1 | Genetic polymorphisms associated with cardiovascular disorders and drug response, methods of detection and uses thereof | CELERA CORP (US) | 2013-04-24 | — | — | EP | disclosed |
| US-8426129-B2 | Method for typing HLA alleles | INNOGENETICS N.V. (BE) | 2013-04-23 | — | — | US | disclosed |
| WO-2013050585-A1 | GENETIC POLYMORPHISMS ASSOCIATED WITH VENOUS THROMBOSIS IN WOMEN, METHODS OF DETECTION AND USES THEREOF | ZOTZ RAINER BERND (DE) | 2013-04-11 | — | — | WO | disclosed |
| US-20130089862-A1 | Genetic Lesion Associated With Cancer | YALE UNIVERSITY (US) | 2013-04-11 | — | — | US | disclosed |
| EP-2578698-A1 | Genetic polymorphisms associated with venous thrombosis in women, methods of detection and uses thereof | Scharf, Rüdiger Eberhard (DE) | 2013-04-10 | — | — | EP | disclosed |
| EP-1583771-B1 | GENETIC POLYMORPHISMS ASSOCIATED WITH MYOCARDIAL INFARCTION, METHODS OF DETECTION AND USES THEREOF | CELERA CORP (US) | 2013-04-03 | — | — | EP | disclosed |
| US-20130078627-A1 | GENETIC POLYMORPHISMS ASSOCIATED WITH LIVER FIBROSIS, METHODS OF DETECTION AND USES THEREOF | Celera Corporation (US) | 2013-03-28 | — | — | US | disclosed |
| EP-1926491-B1 | GENETIC POLYMORPHISMS ASSOCIATED WITH CARDIOVASCULAR DISORDERS AND DRUG RESPONSE, METHODS OF DETECTION AND USES THEREOF | CELERA CORP (US) | 2013-03-20 | — | — | EP | disclosed |
| EP-2064345-B1 | GENETIC POLYMORPHISMS ASSOCIATED WITH PSORIASIS, METHODS OF DETECTION AND USES THEREOF | CELERA CORP (US) | 2013-03-13 | — | — | EP | disclosed |
| US-20130058914-A1 | GENETIC POLYMORPHISMS ASSOCIATED WITH CORONARY EVENTS AND DRUG RESPONSE, METHODS OF DETECTION AND USES THEREOF | Celera Corporation (US) | 2013-03-07 | — | — | US | disclosed |
| EP-2129789-B1 | Method of determining risk associated with breast cancer metastasis by the determination of a molecular prognostic signature. | CELERA CORP (US) | 2013-03-06 | — | — | EP | disclosed |
| EP-2561352-A1 | GENETIC POLYMORPHISMS ASSOCIATED WITH STATIN RESPONSE AND CARDIOVASCULAR DISEASES, METHODS OF DETECTION AND USES THEREOF | Celera Corporation (US) | 2013-02-27 | — | — | EP | disclosed |
| US-20130045198-A1 | GENETIC POLYMORPHISMS ASSOCIATED WITH VENOUS THROMBOSIS, METHODS OF DETECTION AND USES THEREOF | LEIDEN UNIVERSITY MEDICAL CENTER (LUMC), ACTING ON BEHALF OF ACADEMIC HOSPITAL LEIDEN (AZL) (NL) | 2013-02-21 | — | — | US | disclosed |
| EP-2151507-B1 | Genetic polymorphisms associated with myocardial infarction, methods of detection and uses thereof | CELERA CORP (US) | 2013-02-13 | — | — | EP | disclosed |
| US-8372965-B2 | Nucleotide sequences for the detection of enterohaemorrhagic Escherichia coli (EHEC) | BIO-RAD INNOVATIONS (FR) | 2013-02-12 | — | — | US | disclosed |
| US-20130030051-A1 | GENETIC POLYMORPHISMS ASSOCIATED WITH CARDIOVASCULAR DISEASES, METHODS OF DETECTION AND USES THEREOF | UNIVERSITY OF TEXAS BOARD OF REGENTS (US) | 2013-01-31 | — | — | US | disclosed |
| US-20130029327-A1 | GENETIC POLYMORPHISMS ASSOCIATED WITH LIVER FIBROSIS, METHODS OF DETECTION AND USES THEREOF | Celera Corporation (US) | 2013-01-31 | — | — | US | disclosed |
| US-8361728-B2 | Method for diagnosis of glutamate dehydrogenase disorders | PLAITAKIS ANDREAS (GR) | 2013-01-29 | — | — | US | disclosed |
| EP-2217722-B1 | GENETIC POLYMORPHISMS ASSOCIATED WITH LIVER FIBROSIS, METHODS OF DETECTION AND USES THEREOF | CELERA CORP (US) | 2013-01-02 | — | — | EP | disclosed |
| EP-2140024-B1 | Methods and kits for detecting genetic polymorphisms associated with coronary events and drug response | CELERA CORP (US) | 2012-12-19 | — | — | EP | disclosed |
| EP-2113572-B1 | Genetic polymorphisms associated with coronary heart disease, methods of detection and uses thereof | CELERA CORP (US) | 2012-12-05 | — | — | EP | disclosed |
| EP-2524220-A1 | RISK FACTORS OF CIGARETTE SMOKE-INDUCED SPIROMETRIC PHENOTYPES | Lineagen, Inc. (US) | 2012-11-21 | — | — | EP | disclosed |
| WO-2012151305-A2 | GENETIC POLYMORPHISMS ASSOCIATED WITH SHORT STATURE, METHODS OF DETECTION AND USES THEREOF | Celera Corporation (US) | 2012-11-08 | — | — | WO | disclosed |
| EP-2520668-A1 | A molecular prognostic signature for predicting breast cancer distant metastasis, and uses thereof | Celera Corporation (US) | 2012-11-07 | — | — | EP | disclosed |
| US-20120276528-A1 | GENETIC POLYMORPHISMS ASSOCIATED WITH LIVER FIBROSIS METHODS OF DETECTION AND USES THEREOF | Celera Corporation (US) | 2012-11-01 | — | — | US | disclosed |
| US-20120264692-A1 | GENETIC POLYMORPHISMS ASSOCIATED WITH VENOUS THROMBOSIS, METHODS OF DETECTION AND USES THEREOF | Leiden University Medical Center (LUMC) Acting on Behalf of Academic Hospital Leiden (AZL) (NL) | 2012-10-18 | — | — | US | disclosed |
| US-20120258884-A1 | Method of Determining Predisposition to Scoliosis | AXIAL BIOTECH, INC. (US) | 2012-10-11 | — | — | US | disclosed |
| US-20120251539-A1 | Methods and Compositions for the Treatment of Immune Disorders | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-10-04 | — | — | US | disclosed |
| EP-2500440-A2 | Genetic polymorphisms associated with myocardial infarction, methods of detection and uses thereof | Celera Corporation (US) | 2012-09-19 | — | — | EP | disclosed |
| EP-1745154-B1 | GENETIC POLYMORPHISMS ASSOCIATED WITH LIVER FIBROSIS METHODS OF DETECTION AND USES THEREOF | CELERA CORP (US) | 2012-08-01 | — | — | EP | disclosed |
| US-8227189-B2 | Genetic polymorphisms associated with venous thrombosis, methods of detection and uses thereof | Celera Corporation (US) | 2012-07-24 | — | — | US | disclosed |
| US-8221980-B2 | Genetic lesion associated with cancer | YALE UNIVERSITY (US) | 2012-07-17 | — | — | US | disclosed |
| EP-2474631-A2 | Genetic polymorphisms associated with myocardial infarction, methods of detection and uses thereof | Celera Corporation (US) | 2012-07-11 | — | — | EP | disclosed |
| EP-2474630-A2 | Genetic polymorphisms associated with myocardial infarction, methods of detection and uses thereof | Celera Corporation (US) | 2012-07-11 | — | — | EP | disclosed |
| EP-2474632-A2 | Genetic polymorphisms associated with myocardial infarction, methods of detection and uses thereof | Celera Corporation (US) | 2012-07-11 | — | — | EP | disclosed |
| US-8216786-B2 | Genetic polymorphisms associated with cardiovascular diseases, methods of detection and uses thereof | Celera Corporation (US) | 2012-07-10 | — | — | US | disclosed |
| EP-2471953-A1 | Genetic polymorphisms associated with cardiovascular disorders and drug response, methods of detection and uses thereof | Celera Corporation (US) | 2012-07-04 | — | — | EP | disclosed |
| EP-2471952-A1 | Genetic polymorphisms associated with cardiovascular disorders and drug response, methods of detection and uses thereof | Celera Corporation (US) | 2012-07-04 | — | — | EP | disclosed |
| US-8211638-B2 | Genetic polymorphisms associated with liver fibrosis, methods of detection and uses thereof | Celera Corporation (US) | 2012-07-03 | — | — | US | disclosed |
| US-20120156676-A1 | SINGLE NUCLEOTIDE POLYMORPHISMS IN BRCA1 AND CANCER RISK | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-06-21 | — | — | US | disclosed |
| EP-2302075-B1 | Method for typing of HLA alleles | INNOGENETICS NV (BE) | 2012-06-20 | — | — | EP | disclosed |
| EP-1071825-B1 | METHOD FOR TYPING OF HLA ALLELES | INNOGENETICS NV (BE) | 2012-06-20 | — | — | EP | disclosed |
| WO-2012061502-A2 | GENETIC POLYMORPHISMS ASSOCIATED WITH VENOUS THROMBOSIS AND STATIN RESPONSE, METHODS OF DETECTION AND USES THEREOF | Celera Corporation (US) | 2012-05-10 | — | — | WO | disclosed |
| US-20120115131-A1 | GENETIC LESION ASSOCIATED WITH CANCER | YALE UNIVERSITY | 2012-05-10 | — | — | US | disclosed |
| US-20120108651-A1 | GENETIC POLYMORPHISMS ASSOCIATED WITH VENOUS THROMBOSIS AND STATIN RESPONSE, METHODS OF DETECTION AND USES THEREOF | Leiden University Medical Center (LUMC) Acting on Behalf of Academic Hospital Leiden (AZL) (NL) | 2012-05-03 | — | — | US | disclosed |
| EP-2446056-A2 | SINGLE NUCLEOTIDE POLYMORPHISMS IN BRCA1 AND CANCER RISK | Yale University (US) | 2012-05-02 | — | — | EP | disclosed |
| US-20120080324-A1 | METHOD OF ELECTROCHEMICALLY DETECTING TARGET SUBSTANCE, METHOD OF ELECTROCHEMICALLY DETECTING ANALYTE, TEST CHIP, AND DETECTION SET | SYSMEX CORPORATION (JP) | 2012-04-05 | — | — | US | disclosed |
| US-20120082678-A1 | GENETIC POLYMORPHISMS ASSOCIATED WITH PSORIASIS, METHODS OF DETECTION AND USES THEREOF | Celera Corporation (US) | 2012-04-05 | — | — | US | disclosed |
| US-8148070-B2 | Genetic polymorphisms associated with coronary events and drug response, methods of detection and uses thereof | Celera Corporation (US) | 2012-04-03 | — | — | US | disclosed |
| WO-2012035321-A1 | METHODS, COMPOUNDS AND COMPOSITIONS RELATING TO ACTIVATING A LATENT VIRUS | UCL BUSINESS PLC (GB) | 2012-03-22 | — | — | WO | disclosed |
| EP-2431483-A1 | Genetic polymorphisms associated with venous thrombosis, methods of detection and uses thereof | Celera Corporation (US) | 2012-03-21 | — | — | EP | disclosed |
| US-20120065075-A1 | METHOD OF DETERMINING A PREDISPOSITION TO ATRIAL FIBRILLATION (AF) IN A SUBJECT | PROGNOMIX INC. | 2012-03-15 | — | — | US | disclosed |
| US-20120064512-A1 | GENETIC POLYMORPHISMS ASSOCIATED WITH LIVER FIBROSIS, METHODS OF DETECTION AND USES THEREOF | CELERA CORPORTION (US) | 2012-03-15 | — | — | US | disclosed |
| EP-2428201-A1 | Oral administration of nucleoside monophosphates | Merck Serono S.A. (CH) | 2012-03-14 | — | — | EP | disclosed |
| US-8129143-B2 | Transgenic cells comprising peroxisomal membrane polypeptide (PMP) for transport of intracellular proteins to ouside of cell | DSM IP ASSETS B.V. (NL) | 2012-03-06 | — | — | US | disclosed |
| EP-2423326-A2 | Genetic polymorphisms associated with liver fibrosis methods of detection and uses thereof | Celera Corporation (US) | 2012-02-29 | — | — | EP | disclosed |
| EP-2423327-A2 | Genetic polymorphisms associated with liver fibrosis methods of detection and uses thereof | Celera Corporation (US) | 2012-02-29 | — | — | EP | disclosed |
| US-20120039864-A1 | GENETIC POLYMORPHISMS ASSOCIATED WITH VENOUS THROMBOSIS, METHODS OF DETECTION AND USES THEREOF | Leiden University Medical Center (LUMC) Acting on Behalf of Academic Hospital Leiden (AZL) (NL) | 2012-02-16 | — | — | US | disclosed |
| CN-102355906-A | Method for preventing and treating hyperpermeability | APEPTICO FORSCHUNG UND ENTWICK | 2012-02-15 | — | — | CN | disclosed |
| EP-2412826-A2 | Genetic polymorphisms associated with liver fibrosis methods of detection and uses thereof | Celera Corporation (US) | 2012-02-01 | — | — | EP | disclosed |
| EP-2412827-A2 | Genetic polymorphisms associated with liver fibrosis methods of detection and uses thereof | Celera Corporation (US) | 2012-02-01 | — | — | EP | disclosed |
| EP-1799829-B1 | METHOD FOR PRODUCTION OF A COMPOUND IN A EUKARYOTIC CELL | DSM IP ASSETS BV (NL) | 2012-01-18 | — | — | EP | disclosed |
| US-20120010274-A1 | GENETIC POLYMORPHISMS ASSOCIATED WITH PSORIASIS, METHODS OF DETECTION AND USES THEREOF | Celera Corporation (US) | 2012-01-12 | — | — | US | disclosed |
| EP-2405023-A2 | Genetic Polymorphisms Associated with Cardiovascular Disorders and Drug Response, Methods of Detection and Uses Thereof | Celera Corporation (US) | 2012-01-11 | — | — | EP | disclosed |
| US-20110319316-A1 | Method for Preventing and Treating Hyperpermeability | APEPTICO FORSCHUNG UND ENTWICKLUNG GMBH (AT) | 2011-12-29 | — | — | US | disclosed |
| US-8071302-B2 | Genetic polymorphisms associated with liver fibrosis methods of detection and uses thereof | Celera Corporation (US) | 2011-12-06 | — | — | US | disclosed |
| US-8071291-B2 | Genetic polymorphisms associated with venous thrombosis, methods of detection and uses thereof | Celera Corporation (US) | 2011-12-06 | — | — | US | disclosed |
| US-20110293626-A1 | GENETIC POLYMORPHISMS ASSOCIATED WITH RHEUMATOID ARTHRITIS, METHODS OF DETECTION AND USES THEREOF | Celera Corporation (US) | 2011-12-01 | — | — | US | disclosed |
| EP-2386657-A2 | Genetic Polymorphisms Associated with Cardiovascular Disorders and Drug Response, Methods of Detection and Uses Thereof | Celera Corporation (US) | 2011-11-16 | — | — | EP | disclosed |
| EP-2386656-A2 | Genetic Polymorphisms Associated with Cardiovascular Disorders and Drug Response, Methods of Detection and Uses Thereof | Celera Corporation (US) | 2011-11-16 | — | — | EP | disclosed |
| EP-2386658-A2 | Genetic Polymorphisms Associated with Cardiovascular Disorders and Drug Response, Methods of Detection and Uses Thereof | Celera Corporation (US) | 2011-11-16 | — | — | EP | disclosed |
| EP-2386659-A2 | Genetic Polymorphisms Associated with Cardiovascular Disorders and Drug Response, Methods of Detection and Uses Thereof | Celera Corporation (US) | 2011-11-16 | — | — | EP | disclosed |
| US-20110269735-A1 | GENETIC POLYMORPHISMS ASSOCIATED WITH STATIN RESPONSE AND CARDIOVASCULAR DISEASES, METHODS OF DETECTION AND USES THEREOF | Celera Corporation (US) | 2011-11-03 | — | — | US | disclosed |
| WO-2011133418-A1 | GENETIC POLYMORPHISMS ASSOCIATED WITH STATIN RESPONSE AND CARDIOVASCULAR DISEASES, METHODS OF DETECTION AND USES THEREOF | Celera Corporation (US) | 2011-10-27 | — | — | WO | disclosed |
| US-8039212-B2 | Genetic polymorphisms associated with liver fibrosis, methods of detection and uses thereof | Celera Corporation (US) | 2011-10-18 | — | — | US | disclosed |
| US-8040027-B2 | Multi-primary color display and color filter | AU OPTRONICS CORP. (TW) | 2011-10-18 | — | — | US | disclosed |
| EP-2082064-B1 | GENETIC VARIATIONS ASSOCIATED WITH TUMORS | GENENTECH INC (US) | 2011-10-05 | — | — | EP | disclosed |
| US-7993833-B2 | identifying an individual who has an altered risk for developing psoriasis; medcal diagnosis and analysis; detecting a SNP haplotype; drug screening; treatment with biodrugs | Celera Corporation (US) | 2011-08-09 | — | — | US | disclosed |
| US-7993852-B2 | MN/CA IX and cancer prognosis | INSTITUTE OF VIROLOGY OF THE SLOVAK ACADEMY OF SCIENCES (SK) | 2011-08-09 | — | — | US | disclosed |
| WO-2011088476-A1 | RICK FACTORS OF CIGARETTE SMOKE-INDUCED SPIROMETRIC PHENOTYPES | LINEAGEN, INC. (US) | 2011-07-21 | — | — | WO | disclosed |
| US-7977052-B2 | Genetic polymorphisms associated with coronary heart disease, methods of detection and uses thereof | Celera Corporation (US) | 2011-07-12 | — | — | US | disclosed |
| US-7968296-B2 | CACNB2 nucleic acid mutations as indicators of shorter than normal QT interval and ST segment elevation associated with sudden cardiac death | ANTZELEVITCH CHARLES | 2011-06-28 | — | — | US | disclosed |
| WO-2011066284-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF IMMUNE DISORDERS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2011-06-03 | — | — | WO | disclosed |
| US-20110129831-A1 | GENETIC POLYMORPHISMS ASSOCIATED WITH LIVER FIBROSIS METHODS OF DETECTION AND USES THEREOF | Celera Corporation (US) | 2011-06-02 | — | — | US | disclosed |
| US-7947451-B2 | Genetic polymorphisms associated with psoriasis, methods of detection and uses thereof | Celera Corporation (US) | 2011-05-24 | — | — | US | disclosed |
| EP-2322669-A2 | Method for typing and detecting HBV | Innogenetics N.V. (BE) | 2011-05-18 | — | — | EP | disclosed |
| EP-2322670-A2 | Method for typing and detecting HBV | Innogenetics N.V. (BE) | 2011-05-18 | — | — | EP | disclosed |
| EP-2310525-A1 | GENETIC POLYMORPHISMS ASSOCIATED WITH CARDIOVASCULAR DISEASES, METHODS OF DETECTION AND USES THEREOF | Celera Corporation (US) | 2011-04-20 | — | — | EP | disclosed |
| EP-2310533-A2 | GENETIC MARKERS ASSOCIATED WITH DEGENERATIVE DISC DISEASE AND USES THEREOF | Axial Biotech, Inc. (US) | 2011-04-20 | — | — | EP | disclosed |
| US-20110086370-A1 | Protease Detection | MOLOGIC LTD (GB) | 2011-04-14 | — | — | US | disclosed |
| EP-2302075-A2 | Method for typing of HLA alleles | Innogenetics N.V. (BE) | 2011-03-30 | — | — | EP | disclosed |
| US-7910303-B2 | Genetic polymorphisms associated with venous thrombosis, methods of detection and uses thereof | Celera Corporation (US) | 2011-03-22 | — | — | US | disclosed |
| US-20110065209-A1 | Integrated Sample Preparation and Analyte Detection | MBIO DIAGNOSTICS, INC. (US) | 2011-03-17 | — | — | US | disclosed |
| US-20110053165-A1 | CACNB2 NUCLEIC ACID MUTATIONS AS INDICATORS OF SHORTER THAN NORMAL QT INTERVAL AND ST SEGMENT ELEVATION ASSOCIATED WITH SUDDEN CARDIAC DEATH | MASONIC MEDICAL RESEARCH LABORATORY (US) | 2011-03-03 | — | — | US | disclosed |
| US-20110046094-A1 | METHODS AND COMPOSITIONS FOR IDENTIFYING AND TREATING LUPUS | GENENTECH, INC. | 2011-02-24 | — | — | US | disclosed |
| EP-2276855-A2 | GENETIC POLYMORPHISMS ASSOCIATED WIITH VENOUS THROMBOSIS, METHODS OF DETECTION AND USES THEREOF | Celera Corporation (US) | 2011-01-26 | — | — | EP | disclosed |
| US-7875428-B2 | human papillomavirus (HPV); biochips; genotyping | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2011-01-25 | — | — | US | disclosed |
| US-20110015255-A1 | TREATMENT OF AN INFECTION BY AN RNA VIRUS DUE TO AN RNA DEPENDENT RNA POLYMERASE | UNIVERSITÉ VICTOR SEGALEN - BORDEAUX 2 (FR) | 2011-01-20 | — | — | US | disclosed |
| US-7863021-B2 | Genetic polymorphisms associated with rheumatoid arthritis, methods of detection and uses thereof | Celera Corporation (US) | 2011-01-04 | — | — | US | disclosed |
| WO-2010151841-A2 | SINGLE NUCLEOTIDE POLYMORPHISMS IN BRCA1 AND CANCER RISK | YALE UNIVERSITY (US) | 2010-12-29 | — | — | WO | disclosed |
| US-20100323921-A1 | MOLECULAR PROGNOSTIC SIGNATURE FOR PREDICTING BREAST CANCER METASTASIS, AND USES THEREOF | Celera Corporation (US) | 2010-12-23 | — | — | US | disclosed |
| US-20100317639-A1 | Medicament Based On a Monoester of Steroids With Long Chain Fatty Acids | PETRONI ANNA | 2010-12-16 | — | — | US | disclosed |
| EP-2257298-A2 | GENETIC POLYMORPHISMS ASSOCIATED WITH STROKE, METHODS OF DETECTION AND USES THEREOF | Celera Corporation (US) | 2010-12-08 | — | — | EP | disclosed |
| EP-1076720-B1 | NUCLEOTIDE SEQUENCES FOR DETECTING ENTEROHEMORRHAGIC ESCHERICHIA COLI (EHEC) | BIO RAD PASTEUR (FR) | 2010-11-17 | — | — | EP | disclosed |
| US-7833718-B2 | CACNA1C nucleic acid mutations as indicators of shorter than normal QT interval and ST segment elevation associated with sudden cardiac death | MASONIC MEDICAL RESEARCH LABORATORY (US) | 2010-11-16 | — | — | US | disclosed |
| US-7833706-B2 | determining increased risk for developing positive autoantibody rheumatoid factor (RF+) Rheumatoid Arthritis (RA) in human by testing nucleic acid from the human to detect the nucleotide content of a single nucleotide polymorphism (SNP) at position of SEQ ID NOS:1-669 and 1339-49,582 | Celera Corporation (US) | 2010-11-16 | — | — | US | disclosed |
| CN-101294148-B | Method for extracting and purifying high ferro myohemoglobin reductase from myocardium | UNIV NANJING NORMAL | 2010-11-10 | — | — | CN | disclosed |
| EP-0914472-B1 | METHOD FOR TYPING AND DETECTING HBV | INNOGENETICS NV (BE) | 2010-11-03 | — | — | EP | disclosed |
| WO-2010124101-A2 | GENETIC MARKERS ASSOCIATED WITH ENDOMETRIOSIS AND USE THEREOF | JUNEAU BIOSCIENCES, LLC (US) | 2010-10-28 | — | — | WO | disclosed |
| US-20100272713-A1 | Genetic Markers Associated with Endometriosis and Use Thereof | JUNEAU BIOSCIENCES, LLC (US) | 2010-10-28 | — | — | US | disclosed |
| US-7820380-B2 | determining whether a hepatitis C virus-infected human has an increased risk for developing liver fibrosis, comprising testing nucleic acid from the human for a polymorphism in gene TLR4 as represented by position 101 of SEQ ID NO: 18973 or its complement | Celera Corporation (US) | 2010-10-26 | — | — | US | disclosed |
| US-20100267040-A1 | MN/CA IX and Cancer Prognosis | BIOMEDICAL RESEARCH CENTRE OF THE SLOVAK ACADEMY OF SCIENCES (SK) | 2010-10-21 | — | — | US | disclosed |
| EP-1962856-B1 | MEDICAMENT BASED ON A MONOESTER OF STEROIDS WITH LONG CHAIN FATTY ACIDS | PETRONI ANNA (IT) | 2010-10-20 | — | — | EP | disclosed |
| US-7816083-B2 | Genetic polymorphisms associated with neurodegenerative diseases, methods of detection and uses thereof | Celera Corporation (US) | 2010-10-19 | — | — | US | disclosed |
| US-20100261187-A1 | GENETIC POLYMORPHISMS ASSOCIATED WITH CARDIOVASCULAR DISORDERS AND DRUG RESPONSE, METHODS OF DETECTION AND USES THEREOF | Celera Corporation (US) | 2010-10-14 | — | — | US | disclosed |
| US-7811794-B2 | Genetic polymorphisms associated with rheumatoid arthritis, methods of detection and uses thereof | Celera Corporation (US) | 2010-10-12 | — | — | US | disclosed |
| US-7799530-B2 | detecting specific single nucleotide polymorphisms (SNPs) in the human genome, and their association with acute coronary events and/or variability in the responsiveness to statin treatment (including preventive treatment) between different individuals; assessing for risk of heart disease | Celera Corporation (US) | 2010-09-21 | — | — | US | disclosed |
| EP-2222404-A2 | PROTEASE DETECTION | Mologic Ltd (GB) | 2010-09-01 | — | — | EP | disclosed |
| US-20100215645-A1 | determining increased risk for developing positive autoantibody rheumatoid factor (RF+) Rheumatoid Arthritis (RA) in human by testing nucleic acid from the human to detect the nucleotide content of a single nucleotide polymorphism (SNP) at position 101 of any of SEQ ID NOS:10,916-49,582 and 50,231 | Celera Corporation (US) | 2010-08-26 | — | — | US | disclosed |
| US-20100216154-A1 | GENETIC POLYMORPHISMS ASSOCIATED WITH LIVER FIBROSIS, METHODS OF DETECTION AND USES THEREOF | Celera Corporation (US) | 2010-08-26 | — | — | US | disclosed |
| US-7781168-B2 | Genetic polymorphisms associated with myocardial infarction, methods of detection and uses thereof | Celera Corporation (US) | 2010-08-24 | — | — | US | disclosed |
| EP-2217722-A2 | GENETIC POLYMORPHISMS ASSOCIATED WITH LIVER FIBROSIS, METHODS OF DETECTION AND USES THEREOF | Celera Corporation (US) | 2010-08-18 | — | — | EP | disclosed |
| US-20100196400-A1 | GENETIC POLYMORPHISMS ASSOCIATED WITH ALZHEIMER'S DISEASE, METHODS OF DETECTION AND USES THEREOF | Celera Corporation (US) | 2010-08-05 | — | — | US | disclosed |
| US-20100190172-A1 | detecting specific single nucleotide polymorphisms (SNPs) in the human genome, and their association with acute coronary events and/or variability in the responsiveness to statin treatment (including preventive treatment) between different individuals; assessing for risk of heart disease | Celera Corporation (US) | 2010-07-29 | — | — | US | disclosed |
| US-20100190970-A1 | GENETIC LESION ASSOCIATED WITH CANCER | YALE UNIVERSITY | 2010-07-29 | — | — | US | disclosed |
| US-20100183610-A1 | GENETIC POLYMORPHISMS ASSOCIATED WITH ALZHEIMER'S DISEASE, METHODS OF DETECTION AND USES THEREOF | Celera Corporation (US) | 2010-07-22 | — | — | US | disclosed |
| US-20100173312-A1 | GENETIC LESION ASSOCIATED WITH CANCER | YALE UNIVERSITY | 2010-07-08 | — | — | US | disclosed |
| US-20100166880-A1 | Method for treatment and diagnosis of glutamate dehydrogenase disorders | PLAITAKIS ANDREAS | 2010-07-01 | — | — | US | disclosed |
| US-7745213-B2 | Mutations in ion channel proteins associated with sudden cardiac death | MASONIC MEDICAL RESEARCH LABORATORY (US) | 2010-06-29 | — | — | US | disclosed |
| US-7741048-B2 | quantitating levels of MN/CA9 gene expression products in patients afflicted with preneoplastic/neoplastic diseases of tissues, wherein the normal tissue associated with such a preneoplastic/neoplastic disease expresses CA IX, but loses CA IX expression upon carcinogenesis | INSTITUTE OF VIROLOGY OF THE SLOVAK ACADEMY OF SCIENCE (SK) | 2010-06-22 | — | — | US | disclosed |
| US-7727725-B2 | Genetic polymorphisms associated with liver fibrosis, methods of detection and uses thereof | Celera Corporation (US) | 2010-06-01 | — | — | US | disclosed |
| EP-2186913-A2 | Genetic polymorphisms associated with cardiovascular disorders and drug response, methods of detection and uses thereof | Celera Corporation (US) | 2010-05-19 | — | — | EP | disclosed |
| US-20100120040-A1 | GENETIC POLYMORPHISMS ASSOCIATED WITH CORONARY EVENTS AND DRUG RESPONSE, METHODS OF DETECTION AND USES THEREOF | Celera Corporation (US) | 2010-05-13 | — | — | US | disclosed |
| EP-2183386-A1 | A GENETIC LESION ASSOCIATED WITH CANCER | YALE UNIVERSITY (US) | 2010-05-12 | — | — | EP | disclosed |
| US-20100099081-A1 | Method for Typing HLA Alleles | INNOGENETICS N.V. | 2010-04-22 | — | — | US | disclosed |
| US-20100092965-A1 | GENETIC VARIATIONS ASSOCIATED WITH TUMORS | GENENTECH, INC. | 2010-04-15 | — | — | US | disclosed |
| US-7695911-B2 | Genetic polymorphisms associated with Alzheimer's Disease, methods of detection and uses thereof | Celera Corporation (US) | 2010-04-13 | — | — | US | disclosed |
| US-7695915-B2 | measuring the expression level of genes CENPA, PKMYT1, MELK, MYBL2, BUB1, RACGAP1, TK1, UBE2S, DC13, RFC4, PRR11, DIAPH3, ORC6L and CCNB1 in estrogen receptor-positive tumor cells of breast cancer patient, obtaining a metastasis score (MS) based upon the expression levels of said genes | Celera Corporation (US) | 2010-04-13 | — | — | US | disclosed |
| US-7695916-B2 | Genetic polymorphisms associated with coronary events and drug response, methods of detection and uses thereof | Celera Corporation (US) | 2010-04-13 | — | — | US | disclosed |
| US-20100081138-A1 | Nucleotide sequences for the detection of enterohaemorrhagic Escherichia coli (EHEC) | BIO-RAD PASTEUR | 2010-04-01 | — | — | US | disclosed |
| EP-2167659-A2 | GENETIC MARKERS ASSOCIATED WITH ENDOMETRIOSIS AND USE THEREOF | Juneau Biosciences, Llc (US) | 2010-03-31 | — | — | EP | disclosed |
| US-20100055095-A1 | GENETIC VARIATIONS ASSOCIATED WITH TUMORS | GENENTECH, INC. | 2010-03-04 | — | — | US | disclosed |
| EP-2158335-A2 | METHODS AND COMPOSITIONS FOR IDENTIFYING AND TREATING LUPUS | Genetech, Inc. (US) | 2010-03-03 | — | — | EP | disclosed |
| US-20100035983-A1 | GENETIC POLYMORPHISMS ASSOCIATED WITH CARDIOVASCULAR DISEASES, METHODS OF DETECTION AND USES THEREOF | Celera Corporation (US) | 2010-02-11 | — | — | US | disclosed |
| US-20100034821-A1 | GENETIC VARIATIONS ASSOCIATED WITH TUMORS | GENENTECH, INC. | 2010-02-11 | — | — | US | disclosed |
| EP-2151507-A1 | Genetic polymorphisms associated with myocardial infarction, methods of detection and uses thereof | Celera Corporation (US) | 2010-02-10 | — | — | EP | disclosed |
| US-7651840-B2 | Genetic polymorphisms associated with Alzheimer's disease, methods of detection and uses thereof | Celera Corporation (CA) | 2010-01-26 | — | — | US | disclosed |
| US-20100008934-A1 | GENETIC POLYMORPHISMS ASSOCIATED WITH AUTOINFLAMMATORY DISEASES, METHODS OF DETECTION AND USES THEREOF | Celera Corporation (US) | 2010-01-14 | — | — | US | disclosed |
| WO-2010006215-A1 | GENETIC POLYMORPHISMS ASSOCIATED WITH CARDIOVASCULAR DISEASES, METHODS OF DETECTION AND USES THEREOF | Celera Corporation (US) | 2010-01-14 | — | — | WO | disclosed |
| WO-2010002891-A1 | GENETIC POLYMORPHISMS ASSOCIATED WITH AUTOINFLAMMATORY DISEASES, METHODS OF DETECTION AND USES THEREOF | Celera Corporation (US) | 2010-01-07 | — | — | WO | disclosed |
| US-20100003691-A1 | Genetic Markers Associated with Degenerative Disc Disease and Uses Thereof | AXIAL BIOTECH, INC. (US) | 2010-01-07 | — | — | US | disclosed |
| WO-2010003016-A2 | GENETIC MARKERS ASSOCIATED WITH DEGENERATIVE DISC DISEASE AND USES THEREOF | AXIAL BIOTECH, INC (US) | 2010-01-07 | — | — | WO | disclosed |
| EP-2140024-A2 | GENETIC POLYMORPHISMS ASSOCIATED WITH CORONARY EVENTS AND DRUG RESPONSE | Celera Corporation (US) | 2010-01-06 | — | — | EP | disclosed |
| US-20090317905-A1 | MUTATIONS IN ION CHANNEL PROTEINS ASSOCIATED WITH SUDDEN CARDIAC DEATH | MASONIC MEDICAL RESEARCH LABORATORY (US) | 2009-12-24 | — | — | US | disclosed |
| US-20090312410-A1 | Genetic polymorphisms associated with coronary heart disease, methods of detection and uses thereof | APPLERA CORPORATION (US) | 2009-12-17 | — | — | US | disclosed |
| WO-2009151691-A2 | GENETIC POLYMORPHISMS ASSOCIATED WIITH VENOUS THROMBOSIS, METHODS OF DETECTION AND USES THEREOF | Celera Corporation (US) | 2009-12-17 | — | — | WO | disclosed |
| EP-2129789-A2 | A MOLECULAR PROGNOSTIC SIGNATURE FOR PREDICTING BREAST CANCER DISTANT METASTASIS, AND USES THEREOF | Celera Corporation (US) | 2009-12-09 | — | — | EP | disclosed |
| US-7625699-B2 | Using presence of single nucleotide polymorphism (SNP) HCV16165996 as tool in diagnosing cardiovascular disorders | Celera Corporation (US) | 2009-12-01 | — | — | US | disclosed |
| WO-2009140126-A1 | METHOD OF ADMINISTERING A THERAPEUTIC | JUNEAU BIOSCIENCES, LLC (US) | 2009-11-19 | — | — | WO | disclosed |
| EP-2118317-A1 | GENETIC VARIATIONS ASSOCIATED WITH TUMORS | Genentech, Inc. (US) | 2009-11-18 | — | — | EP | disclosed |
| EP-2113572-A1 | Genetic polymorphisms associated with coronary heart disease, methods of detection and uses thereof | Celera Corporation (US) | 2009-11-04 | — | — | EP | disclosed |
| US-20090270332-A1 | GENETIC POLYMORPHISMS ASSOCIATED WITH VENOUS THROMBOSIS, METHODS OF DETECTION AND USES THEREOF | Celera Corporation (US) | 2009-10-29 | — | — | US | disclosed |
| US-20090264453-A1 | GENETIC POLYMORPHISMS ASSOCIATED WITH CORONARY HEART DISEASE, METHODS OF DETECTION AND USES THEREOF | Celera Corporation (US) | 2009-10-22 | — | — | US | disclosed |
| US-20090258003-A1 | Genetic polymorphisms associated with venous thrombosis, methods of detection and uses thereof | APPLERA CORPORATION (US) | 2009-10-15 | — | — | US | disclosed |
| US-7588933-B1 | Nucleotide sequences for detecting enterohaemorrhagic Escherichia coli (EHEC) | BIO-RAD PASTEUR (FR) | 2009-09-15 | — | — | US | disclosed |
| WO-2009109753-A2 | MULTIPLEX SELECTION AND SEQUENCING | MIR KALIM (GB) | 2009-09-11 | — | — | WO | disclosed |
| US-20090221620-A1 | GENTIC POLYMORPHISMS ASSOCIATED WITH STROKE, METHODS OF DETECTION AND USES THEREOF | Celera Corporation (US) | 2009-09-03 | — | — | US | disclosed |
| WO-2009105680-A2 | GENETIC POLYMORPHISMS ASSOCIATED WITH STROKE, METHODS OF DETECTION AND USES THEREOF | Celera Corporation (US) | 2009-08-27 | — | — | WO | disclosed |
| EP-2089540-A2 | GENETIC VARIATIONS ASSOCIATED WITH TUMORS | Genentech, Inc. (US) | 2009-08-19 | — | — | EP | disclosed |
| US-20090203015-A1 | MULTIPLEX ASSAYS FOR HORMONAL AND GROWTH FACTOR RECEPTORS, AND USES THEREOF | Celera Corporation (US) | 2009-08-13 | — | — | US | disclosed |
| WO-2009032316-A9 | GENETIC POLYMORPHISMS ASSOCIATED WITH RHEUMATOID ARHRITIS, METHODS OF DETECTION AND USES THEREOF | SCHRODI STEVEN (US) | 2009-08-13 | — | — | WO | disclosed |
| US-20090196875-A1 | Point mutation analysis of glyceraldehyde-3-phosphate dehydrogenase genes via allele-specific probe hybridization and/or nuclease digestion; kits; drug screening; neurodegenerative disease | Celera Corporation (US) | 2009-08-06 | — | — | US | disclosed |
| US-20090197244-A1 | Method for typing and detecting HBV | INNOGENETICS N.V. (BE) | 2009-08-06 | — | — | US | disclosed |
| EP-2084297-A2 | GENETIC POLYMORPHISMS ASSOCIATED WITH VENOUS THROMBOSIS, METHODS OF DETECTION AND USES THEREOF | Celera Corporation (US) | 2009-08-05 | — | — | EP | disclosed |
| EP-2082064-A2 | GENETIC VARIATIONS ASSOCIATED WITH TUMORS | Genentech, Inc. (US) | 2009-07-29 | — | — | EP | disclosed |
| US-20090176235-A1 | GENETIC POLYMORPHISMS ASSOCIATED WITH MYOCARDIAL INFARCTION, METHODS OF DETECTION AND USES THEREOF | Celera Corporation (US) | 2009-07-09 | — | — | US | disclosed |
| US-20090176240-A1 | MN/CA IX and Cancer Prognosis | BIOMEDICAL RESEARCH CENTRE OF THE SLOVAK ACADEMY OF SCIENCES (SK) | 2009-07-09 | — | — | US | disclosed |
| US-20090170111-A1 | GENETIC POLYMORPHISMS ASSOCIATED WITH STROKE, METHODS OF DETECTION AND USES THEREOF | Celera Corporation (US) | 2009-07-02 | — | — | US | disclosed |
| US-20090162348-A1 | GENETIC POLYMORPHISMS ASSOCIATED WITH PSORIASIS, METHODS OF DETECTION AND USES THEREOF | Celera Corporation (US) | 2009-06-25 | — | — | US | disclosed |
| US-20090162346-A1 | Genetic polymorphisms associated with rheumatoid arthritis, methods of detection and uses thereof | Celera Corporation (US) | 2009-06-25 | — | — | US | disclosed |
| WO-2009073628-A2 | GENETIC POLYMORPHISMS ASSOCIATED WITH PSORIASIS, METHODS OF DETECTION AND USES THEREOF | Celera Corporation (US) | 2009-06-11 | — | — | WO | disclosed |
| US-20090148830-A1 | IDENTIFICATION OF MICROORGANISMS CAUSING ACUTE RESPIRATORY TRACT INFECTIONS (ARI) | INNOGENETICS N.V. (BE) | 2009-06-11 | — | — | US | disclosed |
| EP-2064345-A2 | GENETIC POLYMORPHISMS ASSOCIATED WITH PSORIASIS, METHODS OF DETECTION AND USES THEREOF | Applera Corporation (US) | 2009-06-03 | — | — | EP | disclosed |
| US-7537928-B2 | Mutations in ion channel proteins associated with sudden cardiac death | MASONIC MEDICAL RESEARCH LABORATORY (US) | 2009-05-26 | — | — | US | disclosed |
| WO-2009063208-A2 | PROTEASE DETECTION | MOLOGIC LTD (GB) | 2009-05-22 | — | — | WO | disclosed |
| US-20090130682-A1 | GENETIC POLYMORPHISMS ASSOCIATED WITH LIVER FIBROSIS, METHODS OF DETECTION AND USES THEREOF | Celera Corporation (US) | 2009-05-21 | — | — | US | disclosed |
| WO-2006099365-A9 | GENETIC POLYMORPHISMS ASSOCIATED WITH CORONARY HEART DISEASE, METHODS OF DETECTION AND USES THEREOF | APPLERA CORP (US) | 2009-05-14 | — | — | WO | disclosed |
| WO-2009061799-A2 | GENETIC POLYMORPHISMS ASSOCIATED WITH LIVER FIBROSIS, METHODS OF DETECTION AND USES THEREOF | Celera Corporation (US) | 2009-05-14 | — | — | WO | disclosed |
| US-20090118217-A1 | Genetic polymorphisms associated with myocardial infarction, methods of detection and uses thereof | Celera Corporation (US) | 2009-05-07 | — | — | US | disclosed |
| EP-1673630-A4 | MN/CA IX AND CANCER PROGNOSIS | INST VIROLOGY (SK) | 2009-04-29 | — | — | EP | disclosed |
| CN-100482789-C | Electron donor system for enzymes and its use for the biochemical conversion of substrates | BASF AG (DE) | 2009-04-29 | — | — | CN | disclosed |
| US-7524634-B2 | MN/CA IX and cancer prognosis | INSTITUTE OF VIROLOGY, SLOVAK ACADEMY OF SCIENCES (SK) | 2009-04-28 | — | — | US | disclosed |
| US-20090104620-A1 | Simplified Method of Determining Predisposition to Scoliosis | AXIAL BIOTECH, INC. (US) | 2009-04-23 | — | — | US | disclosed |
| EP-1126828-B1 | ORAL ADMINISTRATION OF ADENOSINE ANALOGS | MAYNE PHARMA PLC (GB) | 2009-04-01 | — | — | EP | disclosed |
| WO-2009032316-A2 | GENETIC POLYMORPHISMS ASSOCIATED WITH RHEUMATOID ARHRITIS, METHODS OF DETECTION AND USES THEREOF | Celera Corporation (US) | 2009-03-12 | — | — | WO | disclosed |
| US-20090068651-A1 | Method for the detection of the antibiotic resistance spectrum of mycobacterium species | INNOGENETICS N.V. (BE) | 2009-03-12 | — | — | US | disclosed |
| US-20090060848-A1 | PHARMACEUTICAL COMPOSITION WHICH REDUCES OR ELIMINATES DRUG ABUSE POTENTIAL | JOSHI YATINDRA | 2009-03-05 | — | — | US | disclosed |
| WO-2008151004-A9 | A GENETIC LESION ASSOCIATED WITH CANCER | UNIV YALE (US) | 2009-02-05 | — | — | WO | disclosed |
| US-20090035772-A1 | Genetic Markers Associated With Scoliosis And Uses Thereof | AXIAL BIOTECH, INC. (US) | 2009-02-05 | — | — | US | disclosed |
| US-20090035769-A1 | Genetic Markers Associated with Scoliosis and Uses Thereof | THIRD SECURITY SENIOR STAFF 2008 LLC | 2009-02-05 | — | — | US | disclosed |
| US-20090035768-A1 | Method of Determining Predisposition to Scoliosis and Uses Thereof | AXIAL BIOTECH, INC. | 2009-02-05 | — | — | US | disclosed |
| EP-2019873-A2 | GENETIC POLYMORPHISMS ASSOCIATED WITH LIVER FIBROSIS, METHODS OF DETECTION AND USES THEREOF | Celera Corporation (US) | 2009-02-04 | — | — | EP | disclosed |
| US-7482117-B2 | Genetic polymorphisms associated with myocardial infarction, methods of detection and uses thereof | Celera Corporation (US) | 2009-01-27 | — | — | US | disclosed |
| EP-2016197-A2 | GENETIC POLYMORPHISMS ASSOCIATED WITH CORONARY HEART DISEASE, METHODS OF DETECTION AND USES THEREOF | Celera (US) | 2009-01-21 | — | — | EP | disclosed |
| WO-2008154352-A2 | GENETIC MARKERS ASSOCIATED WITH ENDOMETRIOSIS AND USE THEREOF | JUNEAU BIOSCIENCES, LLC (US) | 2008-12-18 | — | — | WO | disclosed |
| US-20080305967-A1 | Genetic Markers Associated with Endometriosis and Use Thereof | JUNEAU BIOSCIENCES, LLC (US) | 2008-12-11 | — | — | US | disclosed |
| WO-2008151004-A1 | A GENETIC LESION ASSOCIATED WITH CANCER | YALE UNIVERSITY (US) | 2008-12-11 | — | — | WO | disclosed |
| US-20080306034-A1 | Method of Administering a Therapeutic | JUNEAU BIOSCIENCES, LLC (US) | 2008-12-11 | — | — | US | disclosed |
| US-20080299554-A1 | Genetic polymorphisms associated with liver fibrosis, methods of detection and uses thereof | APPLERA CORPORATION (US) | 2008-12-04 | — | — | US | disclosed |
| WO-2008144761-A2 | METHODS AND COMPOSITIONS FOR IDENTIFYING AND TREATING LUPUS | GENENTECH, INC. (US) | 2008-11-27 | — | — | WO | disclosed |
| US-20080286796-A1 | Genetic polymorphisms associated with neurodegenerative diseases, methods of detection and uses thereof | APPLERA CORPORATION (US) | 2008-11-20 | — | — | US | disclosed |
| WO-2008137121-A2 | METHODS FOR DETECTING AN INCREASED RISK FOR CORONARY HEART DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2008-11-13 | — | — | WO | disclosed |
| WO-2008137110-A1 | GENETIC POLYMORPHISMS ASSOCIATED WITH NEURODEGENERATIVE DISEASES, METHODS OF DETECTION AND USES THEREOF | APPLERA CORPORATION (US) | 2008-11-13 | — | — | WO | disclosed |
| EP-1208238-B1 | Methods of immobilizing ligands on solid supports | MATRIX TECHNOLOGIES CORP (US) | 2008-11-12 | — | — | EP | disclosed |
| US-20080274471-A1 | Methods for detecting an increased risk for coronary heart disease | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2008-11-06 | — | — | US | disclosed |
| CN-101294148-A | Method for extracting and purifying high ferro myohemoglobin reductase from myocardium | UNIV NANJING NORMAL (CN) | 2008-10-29 | — | — | CN | disclosed |
| US-20080248476-A1 | Using presence of single nucleotide polymorphism in fibronectin gene as evaluative indicator of heart disorders | APPLERA CORPORATION (US) | 2008-10-09 | — | — | US | disclosed |
| US-20080241846-A1 | Genetic polymorphisms associated with coronary events and drung response, methods of detection and uses thereof | APPLERA CORPORATION (US) | 2008-10-02 | — | — | US | disclosed |
| WO-2008118415-A2 | GENETIC POLYMORPHISMS ASSOCIATED WITH CORONARY EVENTS AND DRUG RESPONSE | APPLERA CORPORATION (US) | 2008-10-02 | — | — | WO | disclosed |
| EP-1962856-A2 | MEDICAMENT BASED ON A MONOESTER OF STEROIDS WITH LONG CHAIN FATTY ACIDS | Petroni, Anna (IT) | 2008-09-03 | — | — | EP | disclosed |
| US-20080206769-A1 | measuring the expression level of genes CENPA, PKMYT1, MELK, MYBL2, BUB1, RACGAP1, TK1, UBE2S, DC13, RFC4, PRR11, DIAPH3, ORC6L and CCNB1 in estrogen receptor-positive tumor cells of breast cancer patient, obtaining a metastasis score (MS) based upon the expression levels of said genes | APPLERA CORPORATION (US) | 2008-08-28 | — | — | US | disclosed |
| EP-1115885-B1 | IDENTIFICATION OF MICROORGANISMS CAUSING ACUTE RESPIRATORY TRACT INFECTIONS (ARI) | INNOGENETICS NV (BE) | 2008-08-20 | — | — | EP | disclosed |
| WO-2008094678-A2 | A MOLECULAR PROGNOSTIC SIGNATURE FOR PREDICTING BREAST CANCER DISTANT METASTASIS, AND USES THEREOF | APPLERA CORPORATION (US) | 2008-08-07 | — | — | WO | disclosed |
| EP-1948831-A2 | GENETIC POLYMORPHISMS ASSOCIATED WITH ALZHEIMER'S DISEASE, METHODS OF DETECTION AND USES THEREOF | Celera Diagnostics, LLC, . (US) | 2008-07-30 | — | — | EP | disclosed |
| WO-2008089035-A1 | GENETIC VARIATIONS ASSOCIATED WITH TUMORS | GENENTECH, INC. (US) | 2008-07-24 | — | — | WO | disclosed |
| WO-2008070325-A2 | GENETIC VARIATIONS ASSOCIATED WITH TUMORS | GENENTECH, INC. (US) | 2008-06-12 | — | — | WO | disclosed |
| EP-1926491-A2 | GENETIC POLYMORPHISMS ASSOCIATED WITH CARDIOVASCULAR DISORDERS AND DRUG RESPONSE, METHODS OF DETECTION AND USES THEREOF | Celera Diagnostics, LLC, . (US) | 2008-06-04 | — | — | EP | disclosed |
| WO-2008061213-A2 | GENETIC VARIATIONS ASSOCIATED WITH TUMORS | GENENTECH, INC. (US) | 2008-05-22 | — | — | WO | disclosed |
| US-20080118438-A1 | Loss of function mutations in calcium channel polypeptides associated with sudden cardiac death | MASONIC MEDICAL RESEARCH LABORATORY | 2008-05-22 | — | — | US | disclosed |
| US-20080108081-A1 | Genetic polymorphisms associated with coronary stenosis, methods of detection and uses thereof | APPLERA CORPORATION (US) | 2008-05-08 | — | — | US | disclosed |
| US-20080108713-A1 | Genetic polymorphisms associated with psoriasis, methods of detection and uses thereof | APPLERA CORPORATION (US) | 2008-05-08 | — | — | US | disclosed |
| WO-2008051511-A2 | GENETIC POLYMORPHISMS ASSOCIATED WITH VENOUS THROMBOSIS, METHODS OF DETECTION AND USES THEREOF | APPLERA CORPORATION (US) | 2008-05-02 | — | — | WO | disclosed |
| WO-2008049111-A1 | GENETIC MARKERS OF CHROMOSOME 3 ASSOCIATED WITH SCOLIOSIS AND USE THEREOF | AXIAL BIOTECH, INC. (US) | 2008-04-24 | — | — | WO | disclosed |
| EP-0776970-B1 | Stable enzyme composition comprising a thermostable nucleic acid polymerase enzyme | HOFFMANN LA ROCHE (CH) | 2008-04-09 | — | — | EP | disclosed |
| WO-2008033813-A1 | GENETIC MARKERS ON CHROMOSOME 7 ASSOCIATED WITH SCOLIOSIS AND USE THEREOF | AXIAL BIOTECH, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
| WO-2008033239-A2 | GENETIC POLYMORPHISMS ASSOCIATED WITH PSORIASIS, METHODS OF DETECTION AND USES THEREOF | APPLERA (US) | 2008-03-20 | — | — | WO | disclosed |
| US-20080051318-A1 | Genetic polymorphisms associated with Alzheimer's disease, methods of detection and uses thereof | APPLERA CORPORATION (US) | 2008-02-28 | — | — | US | disclosed |
| US-20080026421-A1 | Method for Production of a Compound in a Eukaryotic Cell | DSM IP ASSETS B.V. (NL) | 2008-01-31 | — | — | US | disclosed |
| WO-2008008553-A2 | GENETIC POLYMORPHISMS ASSOCIATED WITH ALZHEIMER'S DISEASE, METHODS OF DETECTION AND USES THEREOF | APPLERA (US) | 2008-01-17 | — | — | WO | disclosed |
| WO-2008006001-A2 | GENETIC POLYMORPHISMS ASSOCIATED WITH SCOLIOSIS AND USE THEREOF | AXIAL BIOTECH, INC. (US) | 2008-01-10 | — | — | WO | disclosed |
| US-20080003603-A1 | HUMAN MELANOMA MUTATION | UNIVERSITY OF UTAH | 2008-01-03 | — | — | US | disclosed |
| US-7313357-B2 | Method for typing and detecting HBV | INNOGENETICS N.V. (BE) | 2007-12-25 | — | — | US | disclosed |
| WO-2007142763-A2 | GENETIC POLYMORPHISMS ASSOCIATED WITH LIVER FIBROSIS, METHODS OF DETECTION AND USES THEREOF | APPLERA (US) | 2007-12-13 | — | — | WO | disclosed |
| US-7306913-B2 | Genetic polymorphisms associated with coronary stenosis, methods of detection and uses thereof | APPLERA CORPORATION (US) | 2007-12-11 | — | — | US | disclosed |
| EP-1856296-A2 | GENETIC POLYMORPHISMS ASSOCIATED WITH CORONARY HEART DISEASE, METHODS OF DETECTION AND USES THEREOF | Applera Corporation (US) | 2007-11-21 | — | — | EP | disclosed |
| US-20070254289-A1 | Genetic polymorphisms associated with Alzheimer's Disease, methods of detection and uses thereof | APPLERA CORPORATION (US) | 2007-11-01 | — | — | US | disclosed |
| WO-2007124157-A2 | GENETIC POLYMORPHISMS ASSOCIATED WITH CORONARY HEART DISEASE, METHODS OF DETECTION AND USES THEREOF | CELERA (US) | 2007-11-01 | — | — | WO | disclosed |
| EP-1660858-A4 | MULTIPLEXED ANALYTE DETECTION | AMPLIFIED PROTEOMICS INC (US) | 2007-10-24 | — | — | EP | disclosed |
| US-20070207456-A1 | Multiplexed assay and probes for identification of HPV types | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2007-09-06 | — | — | US | disclosed |
| US-7252936-B2 | Method for the detection of the antibiotic resistance spectrum of Mycobacterium species | INNOGENETICS N.V. (BE) | 2007-08-07 | — | — | US | disclosed |
| US-20070148247-A1 | Pharmaceutical composition which reduces or eliminates drug abuse potential | JOSHI YATINDRA | 2007-06-28 | — | — | US | disclosed |
| EP-1799829-A2 | METHOD FOR PRODUCTION OF A COMPOUND IN A EUKARYOTIC CELL | DSMIP Assets B.V. (NL) | 2007-06-27 | — | — | EP | disclosed |
| WO-2007068434-A2 | MEDICAMENT BASED ON A MONOESTER OF STEROIDS WITH LONG CHAIN FATTY ACIDS | PETRONI ANNA (IT) | 2007-06-21 | — | — | WO | disclosed |
| WO-2007050705-A2 | GENETIC POLYMORPHISMS ASSOCIATED WITH ALZHEIMER'S DISEASE, METHODS OF DETECTION AND USES THEREOF | CELERA DIAGNOSTICS, LLC. (US) | 2007-05-03 | — | — | WO | disclosed |
| US-20070072821-A1 | Genetic polymorphisms associated with cardiovascular disorders and drug response, methods of detection and uses thereof | APPLERA CORPORATION (US) | 2007-03-29 | — | — | US | disclosed |
| WO-2007035953-A2 | GENETIC POLYMORPHISMS ASSOCIATED WITH CARDIOVASCULAR DISORDERS AND DRUG RESPONSE, METHODS OF DETECTION AND USES THEREOF | CELERA DIAGNOSTICS, LLC. (US) | 2007-03-29 | — | — | WO | disclosed |
| CN-1938046-A | Monomethylvaline compounds capable of coupling to ligands | SEATTLE GENETICS INC (US) | 2007-03-28 | — | — | CN | disclosed |
| US-20070066517-A1 | Composition and method for treating graft-versus-host disease | DIMARTINO JORGE | 2007-03-22 | — | — | US | disclosed |
| US-20070059710-A1 | Genetic polymorphisms associated with stroke, methods of detection and uses thereof | APPLERA CORPORATION (US) | 2007-03-15 | — | — | US | disclosed |
| US-20070054902-A1 | Isoxazole derivatives as peroxisome proliferator-activated receptors agonists | SHIONOGI & CO., LTD. (JP) | 2007-03-08 | — | — | US | disclosed |
| US-20070054278-A1 | Polymorphisms in nucleic acid molecules encoding human enzyme proteins, methods of detection and uses thereof | APPLERA CORPORATION (US) | 2007-03-08 | — | — | US | disclosed |
| US-20070042382-A1 | Genetic polymorphisms associated with myocardial infarction, methods of detection and uses thereof | APPLERA CORPORATION (US) | 2007-02-22 | — | — | US | disclosed |
| US-20070042376-A1 | Mn/ca ix and cancer prognosis | BIOMEDICAL RESEARCH CENTRE OF THE SLOVAK ACADEMY OF SCIENCES (SK) | 2007-02-22 | — | — | US | disclosed |
| EP-1753875-A2 | GENETIC POLYMORPHISMS ASSOCIATED WITH VASCULAR DISEASES, METHODS OF DETECTION AND USES THEREOF | Applera Corporation (US) | 2007-02-21 | — | — | EP | disclosed |
| US-20070031847-A1 | Using presence of single nucleotide polymorphism (SNP) HCV16165996 as tool in diagnosing cardiovascular disorders | APPLERA CORPORATION (US) | 2007-02-08 | — | — | US | disclosed |
| US-20070031846-A1 | determining increased risk for developing positive autoantibody rheumatoid factor (RF+) Rheumatoid Arthritis (RA) in human by testing nucleic acid from the human to detect the nucleotide content of a single nucleotide polymorphism (SNP) at position of SEQ ID NOS:1-669 and 1339-49,582 | APPLERA CORPORATION (US) | 2007-02-08 | — | — | US | disclosed |
| US-20070031848-A1 | Genetic polymorphisms associated with rheumatoid arthritis, methods of detection and uses thereof | APPLERA CORPORATION (US) | 2007-02-08 | — | — | US | disclosed |
| US-7173016-B2 | Composition and method for treating graft-versus-host disease | MAYNE PHARMA (USA) INC. (US) | 2007-02-06 | — | — | US | disclosed |
| EP-1745154-A2 | GENETIC POLYMORPHISMS ASSOCIATED WITH LIVER FIBROSIS METHODS OF DETECTION AND USES THEREOF | Applera Corporation (US) | 2007-01-24 | — | — | EP | disclosed |
| EP-1745147-A2 | GENETIC POLYMORPHISMS ASSOCIATED WITH CORONARY HEART DISEASE, METHODS OF DETECTION AND USES THEREOF | Applera Corporation (US) | 2007-01-24 | — | — | EP | disclosed |
| EP-1741721-A1 | Method for production of a compound in a eukaryotic cell | DSM IP Assets B.V. (NL) | 2007-01-10 | — | — | EP | disclosed |
| EP-1725684-A2 | GENETIC POLYMORPHISMS ASSOCIATED WITH STROKE, METHODS OF DETECTION AND USES THEREOF | Applera Corporation (US) | 2006-11-29 | — | — | EP | disclosed |
| EP-1711622-A2 | GENETIC POLYMORPHISMS ASSOCIATED WITH CARDIOVASCULAR DISORDERS AND DRUG RESPONSE, METHODS OF DETECTION AND USES THEREOF | Applera Corporation (US) | 2006-10-18 | — | — | EP | disclosed |
| EP-1583770-A4 | GENETIC POLYMORPHISMS ASSOCIATED WITH STENOSIS, METHODS OF DETECTION AND USES THEREOF | APPLERA CORP (US) | 2006-10-18 | — | — | EP | disclosed |
| US-20060228715-A1 | Genetic polymorphisms associated with coronary heart disease, methods of detection and uses thereof | APPLERA CORPORATION (US) | 2006-10-12 | — | — | US | disclosed |
| US-20060223093-A1 | Genetic polymorphisms associated with coronary heart disease, methods of detection and uses thereof | APPLERA CORPORATION (US) | 2006-10-05 | — | — | US | disclosed |
| WO-2006099365-A2 | GENETIC POLYMORPHISMS ASSOCIATED WITH CORONARY HEART DISEASE, METHODS OF DETECTION AND USES THEREOF | APPLERA CORPORATION (US) | 2006-09-21 | — | — | WO | disclosed |
| EP-1690538-A1 | ISOXAZOLE DERIVATIVE HAVING AGONISTIC ACTIVITY AGAINST PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR | SHIONOGI & CO., LTD. (JP) | 2006-08-16 | — | — | EP | disclosed |
| EP-1443820-A4 | COMPOSITION AND METHOD FOR TREATING GRAFT-VERSUS-HOST DISEASE | SUPERGEN INC (US) | 2006-07-12 | — | — | EP | disclosed |
| EP-1675968-A2 | AMPLIFICATION OF SIGNAL USING A BEAD-BASED OLIGONUCLEOTIDE ASSAY | THE PROCTER & GAMBLE COMPANY (US) | 2006-07-05 | — | — | EP | disclosed |
| EP-1673630-A2 | MN/CA IX AND CANCER PROGNOSIS | INSTITUTE OF VIROLOGY (SK) | 2006-06-28 | — | — | EP | disclosed |
| EP-1660858-A2 | MULTIPLEXED ANALYTE DETECTION | Wu, Jie (US) | 2006-05-31 | — | — | EP | disclosed |
| US-20060105353-A1 | Non-invasive prenatal fetal cell diagnostic method | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | 2006-05-18 | — | — | US | disclosed |
| US-7037900-B2 | Composition and method for treating graft-versus-host disease | SUPERGEN, INC. (US) | 2006-05-02 | — | — | US | disclosed |
| WO-2006040340-A2 | METHOD FOR PRODUCTION OF A COMPOUND IN A EUKARYOTIC CELL | DSM IP ASSETS B.V. (NL) | 2006-04-20 | — | — | WO | disclosed |
| WO-2006022639-A1 | GENETIC POLYMORPHISMS ASSOCIATED WITH ALZHEIMER'S DISEASE, METHODS OF DETECTION AND USES THEREOF | APPLERA CORPORATION (US) | 2006-03-02 | — | — | WO | disclosed |
| US-20060025359-A1 | Composition and method for treating graft-versus-host disease | MAYNE PHARMA (USA) INC. | 2006-02-02 | — | — | US | disclosed |
| US-20060024700-A1 | determining whether a hepatitis C virus-infected human has an increased risk for developing liver fibrosis, comprising testing nucleic acid from the human for a polymorphism in gene TLR4 as represented by position 101 of SEQ ID NO: 18973 or its complement | APPLERA CORPORATION (US) | 2006-02-02 | — | — | US | disclosed |
| US-20060014168-A1 | Method of diagnosis of inclusion body myopathy-paget bone disease-frontotemporal dementia syndrome | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2006-01-19 | — | — | US | disclosed |
| EP-1613774-A2 | GENETIC POLYMORPHISMS ASSOCIATED WITH STENOSIS, METHODS OF DETECTION AND USES THEREOF | Applera Corporation (US) | 2006-01-11 | — | — | EP | disclosed |
| EP-0966545-B1 | METHOD FOR TYPING OF MINOR HISTOCOMPATIBILITY ANTIGEN HA-1 | UNIV LEIDEN (NL) | 2006-01-04 | — | — | EP | disclosed |
| US-20050287559-A1 | Genetic polymorphisms associated with vascular, methods of detection and uses thereof | APPLERA CORPORATION (US) | 2005-12-29 | — | — | US | disclosed |
| EP-1608782-A2 | GENETIC POLYMORPHISMS ASSOCIATED WITH MYOCARDIAL INFARCTION, METHODS OF DETECTION AND USES THEREOF | Applera Corporation (US) | 2005-12-28 | — | — | EP | disclosed |
| EP-1608783-A2 | GENETIC POLYMORPHISMS ASSOCIATED WITH RHEUMATOID ARTHRITIS, METHODS OF DETECTION AND USES THEREOF | Applera Corporation (US) | 2005-12-28 | — | — | EP | disclosed |
| EP-0999285-B1 | Methods and compositions for amplifying detectable signals in specific binding assays | AFFYMETRIX INC (US) | 2005-12-07 | — | — | EP | disclosed |
| CN-1229371-C | Benzopyran guanidine derivatives, process for preparing the same, and pharmaceutical composition thereof | KOREA RES INST CHEM TECH (KR) | 2005-11-30 | — | — | CN | disclosed |
| WO-2005111241-A2 | GENETIC POLYMORPHISMS ASSOCIATED WITH LIVER FIBROSIS METHODS OF DETECTION AND USES THEREOF | APPLERA CORPORATION (US) | 2005-11-24 | — | — | WO | disclosed |
| US-20050260692-A1 | Positive selection in the immuno-dominant surface antigen 1 (SAG1) of sarcocystis neurona, agent of EPM: potential as a diagnostic reagent and as a component of a sub-unit vaccine | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) | 2005-11-24 | — | — | US | disclosed |
| WO-2005110039-A2 | GENETIC POLYMORPHISMS ASSOCIATED WITH VASCULAR DISEASES, METHODS OF DETECTION AND USES THEREOF | APPLERA CORPORATION (US) | 2005-11-24 | — | — | WO | disclosed |
| EP-1590485-A2 | GENETIC POLYMORPHISMS ASSOCIATED WITH RHEUMATOID ARTHRITIS, METHODS OF DETECTION AND USES THEREOF | Applera Corporation (US) | 2005-11-02 | — | — | EP | disclosed |
| US-20050233350-A1 | Method for typing of minor histocompatibility antigen HA-1 | GOULMY ELSA A J | 2005-10-20 | — | — | US | disclosed |
| EP-1583770-A2 | GENETIC POLYMORPHISMS ASSOCIATED WITH STENOSIS, METHODS OF DETECTION AND USES THEREOF | Applera Corporation (US) | 2005-10-12 | — | — | EP | disclosed |
| EP-1583771-A2 | GENETIC POLYMORPHISMS ASSOCIATED WITH MYOCARDIAL INFARCTION, METHODS OF DETECTION AND USES THEREOF | Applera Corporation (US) | 2005-10-12 | — | — | EP | disclosed |
| WO-2005089264-A2 | METHOD OF DIAGNOSIS OF INCLUSION BODY MYOPATHY - PAGET BONE DISEASE - FRONTOTEMPORAL DEMENTIA SYNDROME | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2005-09-29 | — | — | WO | disclosed |
| WO-2005087953-A2 | GENETIC POLYMORPHISMS ASSOCIATED WITH CORONARY HEART DISEASE, METHODS OF DETECTION AND USES THEREOF | APPLERA CORPORATION (US) | 2005-09-22 | — | — | WO | disclosed |
| WO-2005083127-A2 | GENETIC POLYMORPHISMS ASSOCIATED WITH STROKE, METHODS OF DETECTION AND USES THEREOF | APPLERA CORPORATION (US) | 2005-09-09 | — | — | WO | disclosed |
| US-20050175990-A1 | Using core region specific probes to classifiy hepatitis b viral genotypes | INNOGENETICS N.V. | 2005-08-11 | — | — | US | disclosed |
| WO-2005056837-A2 | GENETIC POLYMORPHISMS ASSOCIATED WITH CARDIOVASCULAR DISORDERS AND DRUG RESPONSE, METHODS OF DETECTION AND USES THEREOF | APPLERA CORPORATION (US) | 2005-06-23 | — | — | WO | disclosed |
| US-20050130190-A1 | Mutations in ion channel proteins associated with sudden cardiac death | MASONIC MEDICAL RESEARCH LABORATORY | 2005-06-16 | — | — | US | disclosed |
| WO-2005040429-A2 | AMPLIFICATION OF SIGNAL USING A BEAD-BASED OLIGONUCLEOTIDE ASSAY | THE PROCTER & GAMBLE COMPANY (US) | 2005-05-06 | — | — | WO | disclosed |
| WO-2005037083-A2 | MN/CA IX AND CANCER PROGNOSIS | BAYER HEALTHCARE (US) | 2005-04-28 | — | — | WO | disclosed |
| US-20050089874-A1 | Amplification of signal using a bead-based oligonucleotide assay | PROCTER & GAMBLE COMPANY, THE | 2005-04-28 | — | — | US | disclosed |
| US-20050079520-A1 | Quantitating or detecting the presence of a plurality of different target molecules in a sample using detector molecules comprising nucleic acid tags | AMPLIFIED PROTEOMICS INC. | 2005-04-14 | — | — | US | disclosed |
| US-20050048562-A1 | Methods and compositions for detecting signals in binding assays | AFFYMETRIX, INC. (US) | 2005-03-03 | — | — | US | disclosed |
| US-20050026169-A1 | Genetic polymorphisms associated with myocardial infarction, methods of detection and uses thereof | APPLERA CORPORATION (US) | 2005-02-03 | — | — | US | disclosed |
| WO-2005010494-A2 | MULTIPLEXED ANALYTE DETECTION | WU JIE (US) | 2005-02-03 | — | — | WO | disclosed |
| US-20040265849-A1 | Point mutation analysis of glyceraldehyde-3-phosphate dehydrogenase genes via allele-specific probe hybridization and/or nuclease digestion; kits; drug screening | APPLERA CORPORATION | 2004-12-30 | — | — | US | disclosed |
| US-6830883-B1 | Method for typing of minor histocompatibility antigen HA-1 | RIJKSUNIVERSITEIT LEIDEN (NL) | 2004-12-14 | — | — | US | disclosed |
| EP-0258017-B2 | Purified thermostable enzyme and process for amplifying, detecting, and/or cloning nucleic acid sequences using said enzyme | HOFFMANN LA ROCHE (CH) | 2004-12-01 | — | — | EP | disclosed |
| US-6806047-B2 | DETECTING TARGET; COMPLEXING | AFFYMETRIX, INC. | 2004-10-19 | — | — | US | disclosed |
| US-6803187-B1 | ALLOWING THE SIMULTANEOUS CHARATERIZATION OF A RANGE OF CODONS INVOLVED IN DRUG RESISTANCE USING SPECIFIC SETS OF PROBES OPTIMIZED TO FUNCTION TOGETHER IN A REVERSE-HYBRIDIZATION ASSAY; SOLID PHASE SYNTHESIS | INNOGENETICS N.V. (BE) | 2004-10-12 | — | — | US | disclosed |
| US-6803196-B1 | Methods and compositions for detecting signals in binding assays using microparticles | AFFYMETRIX, INC. | 2004-10-12 | — | — | US | disclosed |
| WO-2004083403-A2 | GENETIC POLYMORPHISMS ASSOCIATED WITH RHEUMATOID ARTHRITIS, METHODS OF DETECTION AND USES THEREOF | APPLERA CORPORATION (US) | 2004-09-30 | — | — | WO | disclosed |
| WO-2004081187-A2 | GENETIC POLYMORPHISMS ASSOCIATED WITH MYOCARDIAL INFARCTION, METHODS OF DETECTION AND USES THEREOF | APPLERA CORPORATION (US) | 2004-09-23 | — | — | WO | disclosed |
| WO-2004081186-A2 | SINGLE NUCLEOTIDE POLYMORPHISMS ASSOCIATED WITH STENOSIS, METHODS OF DETECTION AND USES THEREOF | APPLERA CORPORATION (US) | 2004-09-23 | — | — | WO | disclosed |
| US-20040166519-A1 | Genetic polymorphisms associated with stenosis, methods of detection and uses thereof | APPLERA CORPORATION | 2004-08-26 | — | — | US | disclosed |
| WO-2004067779-A2 | GENETIC POLYMORPHISMS ASSOCIATED WITH RHEUMATOID ARTHRITIS, METHODS OF DETECTION AND USES THEREOF | APPLERA CORPORATION (US) | 2004-08-12 | — | — | WO | disclosed |
| EP-1443820-A1 | COMPOSITION AND METHOD FOR TREATING GRAFT-VERSUS-HOST DISEASE | SuperGen, Inc. (US) | 2004-08-11 | — | — | EP | disclosed |
| WO-2004058990-A2 | GENETIC POLYMORPHISMS ASSOCIATED WITH STENOSIS, METHODS OF DETECTION AND USES THEREOF | APPLERA CORPORATION (US) | 2004-07-15 | — | — | WO | disclosed |
| WO-2004058052-A2 | GENETIC POLYMORPHISMS ASSOCIATED WITH MYOCARDIAL INFARCTION, METHODS OF DETECTION AND USES THEREOF | APPLERA CORPORATION (US) | 2004-07-15 | — | — | WO | disclosed |
| US-20040137493-A1 | Methods and compositions for amplifying detectable signals in specific binding assays | AFFYMETRIX, INC. | 2004-07-15 | — | — | US | disclosed |
| US-20040127404-A1 | Methods for treating autoimmune diseases | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2004-07-01 | — | — | US | disclosed |
| US-20040116411-A1 | Combination HIV therapy including camptothecin | SUPERGEN, INC., A DELAWARE CORPORATION | 2004-06-17 | — | — | US | disclosed |
| US-6713251-B2 | DETECTING SENSITIVITY OF VIRUSES TO VIRICIDES; OBTAIN SAMPLE, AMPLIFY NUCLEOTIDE SEQUENCES, HYBRIDIZE WITH PROBES, DETECT HYBRIDS, DETERMINE NUCLEOTIDE SEQUENCES, EVALUATE VIRICIDE SENSITIVITY | INNOGENETICS N.V. (BE) | 2004-03-30 | — | — | US | disclosed |
| US-6709812-B1 | PROBE HYBRIDIZES SPECIFICALLY TO A MUTANT HBV RT POL GENE TARGET SEQUENCE AND IDENTIFIES DRUG RESISTANT HBV STRAINS | INNOGENETICS N.V. (BE) | 2004-03-23 | — | — | US | disclosed |
| EP-0771360-B1 | METHOD FOR THE DETECTION OF THE ANTIBIOTIC RESISTANCE SPECTRUM OF MYCOBACTERIUM SPECIES | INNOGENETICS NV (BE) | 2004-03-10 | — | — | EP | disclosed |
| US-20040042964-A1 | Pharmaceutical composition which reduces or eliminates drug abuse potential | JOSHI YATINDRA (US) | 2004-03-04 | — | — | US | disclosed |
| US-20040029110-A1 | Hepatitis B virus (HBV); releasing, isolating or concentrating the polynucleic acids; amplification; hybridization to a mutant target sequence such as pol gene region | INNOGENETICS N.V. | 2004-02-12 | — | — | US | disclosed |
| US-6632607-B1 | Drug resistance; Mycobacterium tuberculosis; use of probes, primers, methods and kits comprising the same for the detection of mycobacterial nucleic acids in biological samples | INNOGENETICS N.V. (BE) | 2003-10-14 | — | — | US | disclosed |
| US-20030180763-A1 | Method for typing of HLA alleles | INNOGENETICS N.V. | 2003-09-25 | — | — | US | disclosed |
| US-20030175746-A1 | Probes, methods and kits for detection and typing of Helicobacter pylori nucleic acids in biological samples | QUINT WILHELMUS (NL) | 2003-09-18 | — | — | US | disclosed |
| US-20030165821-A1 | Detection and identification of human papillomavirus by PCR and type-specific reverse hybridization | INNOGENETICS S.A. | 2003-09-04 | — | — | US | disclosed |
| US-20030165860-A1 | Probes, methods and kits for detection and typing of Helicobacter pylori nucleic acids in biological samples | QUINT WILHELMUS (NL) | 2003-09-04 | — | — | US | disclosed |
| CN-1118460-C | As 5HTzcPyrimidine derivatives as receptor antagonists | HOFFMANN LA ROCHE (CH) | 2003-08-20 | — | — | CN | disclosed |
| US-20030152982-A1 | Method for the detection of the antibiotic resistance spectrum of Mycobacterium species | DE BEENHOUWER HANS (BE) | 2003-08-14 | — | — | US | disclosed |
| WO-2002028530-A9 | SELF-ENCODING SENSOR ARRAYS WITH MICROSPHERES | TUFTS COLLEGE (US) | 2003-08-14 | — | — | WO | disclosed |
| US-20030147975-A1 | Pharmaceutical composition which produces irritation | JOSHI YATINDRA (US) | 2003-08-07 | — | — | US | disclosed |
| US-20030143570-A1 | Methods of immobilizing ligands on solid supports and apparatus and methods of use therefor | MATRIX TECHNOLOGIES CORPORATION | 2003-07-31 | — | — | US | disclosed |
| US-20030143569-A1 | Methods of immobilizing ligands on solid supports and apparatus and methods of use therefor | MATRIX TECHNOLOGIES CORPORATION (US) | 2003-07-31 | — | — | US | disclosed |
| CN-1111529-C | Piperazino-derivatives as neurokinin | SCHERING CORP (US) | 2003-06-18 | — | — | CN | disclosed |
| EP-1311266-A2 | COMBINATION HIV THERAPY INCLUDING CAMPTOTHECIN | SuperGen, Inc. (US) | 2003-05-21 | — | — | EP | disclosed |
| US-20030077575-A1 | Method for detection of drug-induced mutations in the reverse transcriptase gene | INNOGENETICS N.V. | 2003-04-24 | — | — | US | disclosed |
| WO-2003030643-A1 | COMPOSITION AND METHOD FOR TREATING GRAFT-VERSUS-HOST DISEASE | SUPERGEN, INC. (US) | 2003-04-17 | — | — | WO | disclosed |
| US-20030073649-A1 | Composition and method for treating graft-versus-host disease | MAYNE PHARMA (USA) INC. | 2003-04-17 | — | — | US | disclosed |
| US-20030049272-A1 | Pharmaceutical composition which produces irritation | JOSHI YATINDRA (US) | 2003-03-13 | — | — | US | disclosed |
| WO-2003018015-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING DRUG ABUSE BY PPRODUCING MUSOUS MEMBRANE IRRITATION | NOVARTIS AG (CH) | 2003-03-06 | — | — | WO | disclosed |
| US-6528261-B1 | Given nucleotide sequence of exons; amplifying nucleic acids; hybridizing to probe that specifically hybridizes to a target region comprising polymorphic nucleotides | INNOGENETICS N.V. (BE) | 2003-03-04 | — | — | US | disclosed |
| US-20030027174-A1 | Identification of nucleotide sequences specific for mycobacteria and development of differential diagnosis strategies for mycobacterial species | GALA JEAN-LUC (BE) | 2003-02-06 | — | — | US | disclosed |
| US-6514736-B1 | Oligonucleotide primers which also contain a non-complemetary sequence, labeled probes, and a thermostable DNA polymerase enzyme; | ROCHE MOLECULAR SYSTEMS, INC | 2003-02-04 | — | — | US | disclosed |
| US-20020187192-A1 | Pharmaceutical composition which reduces or eliminates drug abuse potential | JOSHI YATINDRA (US) | 2002-12-12 | — | — | US | disclosed |
| US-6492118-B1 | PROVIDING A SOLID SUPPORT CONTAINING AN IMMOBILIZED LATENT THIOL GROUP, ACTIVATING THE THIOL GROUP, CONTACTING WITH A NUCLEIC ACID COMPRISING AN ACRYLAMIDE FUNCTIONAL GROUP, AND FORMING A COVALENT BOND BETWEEN THE TWO GROUPS | MATRIX TECHNOLOGIES CORPORATION | 2002-12-10 | — | — | US | disclosed |
| CN-1382134-A | Benzopyranyl guanidine derivtives, process for preparation thereof and pharmaceutical compositions containing them | KOREA RES INST CHEM TECH (KR) | 2002-11-27 | — | — | CN | disclosed |
| US-6482588-B1 | Detection and identification of human papillomavirus by PCR and type-specific reverse hybridization | INNOGENETICS S.A. (BE) | 2002-11-19 | — | — | US | disclosed |
| WO-2002087558-A1 | PHARMACEUTICAL COMPOSITION WHICH REDUCES OR ELIMINATES DRUG ABUSE POTENTIAL | NOVARTIS AG (CH) | 2002-11-07 | — | — | WO | disclosed |
| CN-1376194-A | Electron donor system for enzymes and its use for the biochemical conversion of substrates | BASF AG (DE) | 2002-10-23 | — | — | CN | disclosed |
| CN-1092197-C | Bicyclic thiophene derivatives and use as gonadotropin releasing hormone antagonists | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2002-10-09 | — | — | CN | disclosed |
| WO-2001016372-A9 | METHODS OF IMMOBILIZING LIGANDS ON SOLID SUPPORTS AND APPARATUS AND METHODS OF USE THEREFOR | MATRIX TECHNOLOGIES CORP (US) | 2002-09-12 | — | — | WO | disclosed |
| EP-1233076-A2 | Differential diagnosis for mycobacterial and pseudomonas species using species-specific upstream p34 gene region probes | UNIVERSITE CATHOLIQUE DE LOUVAIN (BE) | 2002-08-21 | — | — | EP | disclosed |
| EP-1012348-B1 | DETECTION AND IDENTIFICATION OF HUMAN PAPILLOMAVIRUS BY PCR AND TYPE-SPECIFIC REVERSE HYBRIDIZATION | INNOGENETICS NV (BE) | 2002-06-12 | — | — | EP | disclosed |
| EP-1208238-A1 | METHODS OF IMMOBILIZING LIGANDS ON SOLID SUPPORTS AND APPARATUS AND METHODS OF USE THEREFOR | Mosaic Technologies (US) | 2002-05-29 | — | — | EP | disclosed |
| US-6387945-B2 | REACTING AN AMINE AND A CARBOXY-1,2-DITHIOLANE DERIVATIVE TO PRODUCE COMPOUNDS SUCH AS N,N-DIMETHYL-N-2-AMIDOETHYL LIPOATE USED TO TREAT CONDITIONS INVOLVING REACTIVE OXYGEN SPECIES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2002-05-14 | — | — | US | disclosed |
| EP-1200102-A1 | METHODS FOR TREATING AUTOIMMUNE DISEASES | Supergen, Inc. (US) | 2002-05-02 | — | — | EP | disclosed |
| EP-1201771-A2 | Detection and identification of human papillomavirus by PCR and type-specific reverse hybridization | INNOGENETICS N.V. (BE) | 2002-05-02 | — | — | EP | disclosed |
| WO-2002028530-A2 | SELF-ENCODING SENSOR ARRAYS WITH MICROSPHERES | TRUSTEES OF TUFTS COLLEGE (US) | 2002-04-11 | — | — | WO | disclosed |
| WO-2002000168-A2 | COMBINATION HIV THERAPY INCLUDING CAMPTOTHECIN | SUPERGEN, INC. (US) | 2002-01-03 | — | — | WO | disclosed |
| US-6331389-B1 | DETERMINING SENSITIVITY OF VIRICIDES; HYBRIDIZE NUCLEOTIDE SEQUENCES, DETECT HYBRIDS, DETERMINE NUCLEOTIDE SEQUENCES FROM HYBRIDIZATION SIGNAL, CLASSIFY VIRAL SEQUENCES | INNOGENETICS N.V. (BE) | 2001-12-18 | — | — | US | disclosed |
| US-6329138-B1 | DETERMINING ANTIBIOTIC RESISTANCE OF MYCOBACTERIAL IN ABIOLOGICAL SAMPLE BY HYBRIDIZING A MUTANT PROBE FROM THE MYCOBACTERIUM TUBERCULOSIS WITH A NUCLEIC ACID FROM THE SAMPLE, DETECTING HYBRIDS INFERRING RIFAMPICIN RESISTANCE | INNOGENETICS, N.V. (BE) | 2001-12-11 | — | — | US | disclosed |
| EP-1144693-A3 | DETECTION OF ANTI-HEPATITIS B DRUG RESISTANCE | INNOGENETICS N.V. (BE) | 2001-11-28 | — | — | EP | disclosed |
| US-20010041335-A1 | Methods and compositions for amplifying detectable signals in specific binding assays | AFFYMETRIX, INC. | 2001-11-15 | — | — | US | disclosed |
| US-20010039292-A1 | Lipoic acid analogs | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, A CALIFORNIA CORPORATION | 2001-11-08 | — | — | US | disclosed |
| EP-1144693-A2 | DETECTION OF ANTI-HEPATITIS B DRUG RESISTANCE | INNOGENETICS N.V. (BE) | 2001-10-17 | — | — | EP | disclosed |
| EP-1126828-A1 | ORAL ADMINISTRATION OF ADENOSINE ANALOGS | SuperGen, Inc. (US) | 2001-08-29 | — | — | EP | disclosed |
| CN-1070048-C | Hair coloring composition | BRISTOL MYERS SQUIBB CO (US) | 2001-08-29 | — | — | CN | disclosed |
| EP-1115885-A1 | IDENTIFICATION OF MICROORGANISMS CAUSING ACUTE RESPIRATORY TRACT INFECTIONS (ARI) | INNOGENETICS N.V. (BE) | 2001-07-18 | — | — | EP | disclosed |
| US-6252057-B1 | POLYPEPTIDE; FOR THE AMPLIFICATION OF GLUCAN POLYSACCHARIDES IN CELL | WARNER-LAMBERT COMPANY | 2001-06-26 | — | — | US | disclosed |
| EP-1090147-A2 | METHOD FOR DETECTION OF DRUG-SELECTED MUTATIONS IN THE HIV PROTEASE GENE | INNOGENETICS N.V. (BE) | 2001-04-11 | — | — | EP | disclosed |
| US-6203989-B1 | HYBRIDIZING PROBE TO TARGET NUCLEIC ACID HAVING BINDING LIGAND, CONTACTING WITH MULTIPLE SITE RECEPTOR WHICH BINDS THE LIGAND, CONTACTING RECEPTOR WITH BINDING LIGANDS WHICH COMPLEX TO RECEPTOR, THEN DETECTING THE COMPLEX | AFFYMETRIX, INC. | 2001-03-20 | — | — | US | disclosed |
| WO-2000055338-A9 | SESQUITERPENOID SYNTHASE GENES AND THEIR USE FOR INFLUENCING BITTERNESS AND RESISTANCE IN PLANTS | RES INST FOR AGROBIOLOGY AND S (NL) | 2001-03-15 | — | — | WO | disclosed |
| WO-2001016372-A1 | METHODS OF IMMOBILIZING LIGANDS ON SOLID SUPPORTS AND APPARATUS AND METHODS OF USE THEREFOR | MATRIX TECHNOLOGIES CORPORATION (US) | 2001-03-08 | — | — | WO | disclosed |
| US-6197563-B1 | ACCUMULATION OF NUCLEOTIDE SEQUENCES; FOR DIAGNOSIS OF INFECTIONS AND SCREENING FOR NUCLEOTIDE SEQUENCE POLYMORPHISMS | ROCHE MOLECULAR SYSTEMS, INC. | 2001-03-06 | — | — | US | disclosed |
| US-6194561-B1 | OLIGONUCLEOTIDE PROBES OF DEFINED NUCLEOTIDE SEQUENCES WHICH ARE COMPLEMENTARY TO SECOND EXON OF CLASS II HLA BETA CHAIN GENE; DIAGNOSIS OF SUSCEPTIBILITY TO INSULIN-DEPENDENT DIABETES MELLITUS AND PEMPHIGUS VULGARIS; ANTIDIABETIC AGENTS | ROCHE MOLECULAR SYSTEMS, INC. | 2001-02-27 | — | — | US | disclosed |
| EP-1076720-A2 | NUCLEOTIDE SEQUENCES FOR DETECTING ENTEROHEMORRHAGIC $i(ESCHERICHIA COLI) (EHEC) | Bio-Rad Pasteur (FR) | 2001-02-21 | — | — | EP | disclosed |
| US-6191162-B1 | ADMINISTERING LIPOIC ACID | MEDICAL RESEARCH INSTITUTE | 2001-02-20 | — | — | US | disclosed |
| WO-2001007054-A1 | METHODS FOR TREATING AUTOIMMUNE DISEASES | SUPERGEN, INC. (US) | 2001-02-01 | — | — | WO | disclosed |
| EP-1071825-A2 | METHOD FOR TYPING OF HLA ALLELES | INNOGENETICS N.V. (BE) | 2001-01-31 | — | — | EP | disclosed |
| WO-2001004358-A2 | DETECTION OF ANTI-HEPATITIS B DRUG RESISTANCE | INNOGENETICS N.V. (BE) | 2001-01-18 | — | — | WO | disclosed |
| US-6174873-B1 | ADMINISTERING BY MOUTH AN ACID-LABILE 2'-DEOXYADENOSINE ANALOG THAT IS ISOLATED FROM THE STOMACH ACID; PROTECTIVE COATINGS; ERODIBLE MATRIX, SOLID DISPERSION, AND ION EXCHANGE RESINT; ANTICARCINOGENIC,-TUMOR AGENTS | SUPERGEN, INC. | 2001-01-16 | — | — | US | disclosed |
| EP-1061914-A1 | LIPOIC ACID ANALOGS | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2000-12-27 | — | — | EP | disclosed |
| WO-2000055338-A1 | SESQUITERPENOID SYNTHASE GENES AND THEIR USE FOR INFLUENCING BITTERNESS AND RESISTANCE IN PLANTS | RESEARCH INSTITUTE FOR AGROBIOLOGY AND SOIL FERTILITY (AB-DLO) (NL) | 2000-09-21 | — | — | WO | disclosed |
| EP-1035219-A1 | Gastric helicobacter 16 S rDNA sequences from cattle and pigs and their use for detection and typing of Helicobacter strains | UNIVERSITEIT GENT (BE) | 2000-09-13 | — | — | EP | disclosed |
| WO-2000018962-A9 | METHODS AND COMPOSITIONS FOR AMPLIFYING DETECTABLE SIGNALS IN SPECIFIC BINDING ASSAYS | AFFYMETRIX INC (US) | 2000-08-24 | — | — | WO | disclosed |
| EP-1029082-A2 | DETECTION AND TYPING OF THE $i(iceA) GENE OF $i(HELICOBACTER PYLORI) | INNOGENETICS N.V. (BE) | 2000-08-23 | — | — | EP | disclosed |
| US-6090842-A | REDUCES CONCENTRATION OF OXYGEN IN CELLS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2000-07-18 | — | — | US | disclosed |
| US-6087093-A | SCREENING SENSITIVITY OF VIRUSES TO ANTIVIRAL DRUGS; HYBRIDIZING NUCLEIC ACIDS IN SAMPLE WITH AT LEAST TWO REVERSE TRANSCRIPTASE GENE PROBES, DETECTING HYBRIDS AND DETERMINING SEQUENCE OF CODONS | INNOGENETICS N.V. (BE) | 2000-07-11 | — | — | US | disclosed |
| EP-1012348-A2 | DETECTION AND IDENTIFICATION OF HUMAN PAPILLOMAVIRUS BY PCR AND TYPE-SPECIFIC REVERSE HYBRIDIZATION | INNOGENETICS N.V. (BE) | 2000-06-28 | — | — | EP | disclosed |
| WO-2000025758-A1 | ORAL ADMINISTRATION OF ADENOSINE ANALOGS | SUPERGEN, INC. (US) | 2000-05-11 | — | — | WO | disclosed |
| EP-0999285-A1 | Methods and compositions for amplifying detectable signals in specific binding assays | Affymetrix, Inc. (a California Corporation) (US) | 2000-05-10 | — | — | EP | disclosed |
| WO-2000018962-A1 | METHODS AND COMPOSITIONS FOR AMPLIFYING DETECTABLE SIGNALS IN SPECIFIC BINDING ASSAYS | AFFYMETRIX, INC. (US) | 2000-04-06 | — | — | WO | disclosed |
| WO-2000017391-A1 | IDENTIFICATION OF MICROORGANISMS CAUSING ACUTE RESPIRATORY TRACT INFECTIONS (ARI) | INNOGENETICS N.V. (BE) | 2000-03-30 | — | — | WO | disclosed |
| US-6040166-A | CONTAINING TWO DIFFERING OLIGONUCLEOTIDE PRIMERS, A OLIGONUCLEOTIDE PROBE AND A DNA POLYMERASE | ROCHE MOLECULAR SYSTEMS, INC. (US) | 2000-03-21 | — | — | US | disclosed |
| WO-1999067428-A2 | METHOD FOR DETECTION OF DRUG-SELECTED MUTATIONS IN THE HIV PROTEASE GENE | INNOGENETICS N.V. (BE) | 1999-12-29 | — | — | WO | disclosed |
| EP-0966545-A2 | METHOD FOR TYPING OF MINOR HISTOCOMPATIBILITY ANTIGEN HA-1 | RIJKSUNIVERSITEIT LEIDEN (NL) | 1999-12-29 | — | — | EP | disclosed |
| EP-0965648-A1 | Method for genomic typing of the Minor Histocomptability Antigen HA-1. | RIJKSUNIVERSITEIT LEIDEN (NL) | 1999-12-22 | — | — | EP | disclosed |
| WO-1999055908-A2 | NUCLEOTIDE SEQUENCES FOR DETECTING ENTEROHEMORRHAGIC ESCHERICHIA COLI (EHEC) | BIO-RAD PASTEUR (FR) | 1999-11-04 | — | — | WO | disclosed |
| EP-0953650-A1 | Method for typing of HLA alleles | INNOGENETICS N.V. (BE) | 1999-11-03 | — | — | EP | disclosed |
| WO-1999054496-A2 | METHOD FOR TYPING OF HLA ALLELES | INNOGENETICS N.V. (BE) | 1999-10-28 | — | — | WO | disclosed |
| EP-0946747-A2 | PROBES, METHODS AND KITS FOR DETECTION AND TYPING OF HELICOBACTER PYLORI NUCLEIC ACIDS IN BIOLOGICAL SAMPLES | INNOGENETICS N.V. (BE) | 1999-10-06 | — | — | EP | disclosed |
| WO-1999045922-A1 | LIPOIC ACID ANALOGS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1999-09-16 | — | — | WO | disclosed |
| EP-0941324-A1 | PROTEIN TARGETING TO GLYCOGEN | WARNER-LAMBERT COMPANY (US) | 1999-09-15 | — | — | EP | disclosed |
| WO-1999024607-A9 | DETECTION AND TYPING OF THE iceA GENE OF $i(HELICOBACTER PYLORI) | INNOGENETICS NV (BE) | 1999-08-12 | — | — | WO | disclosed |
| WO-1999024607-A2 | DETECTION AND TYPING OF THE iceA GENE OF $i(HELICOBACTER PYLORI) | INNOGENETICS N.V. (BE) | 1999-05-20 | — | — | WO | disclosed |
| EP-0914472-A2 | METHOD FOR TYPING AND DETECTING HBV | INNOGENETICS N.V. (BE) | 1999-05-12 | — | — | EP | disclosed |
| WO-1999014377-A2 | DETECTION AND IDENTIFICATION OF HUMAN PAPILLOMAVIRUS BY PCR AND TYPE-SPECIFIC REVERSE HYBRIDIZATION | INNOGENETICS N.V. (BE) | 1999-03-25 | — | — | WO | disclosed |
| WO-1999005313-A2 | METHOD FOR TYPING OF MINOR HISTOCOMPATIBILITY ANTIGEN HA-1 | RIJKSUNIVERSITEIT LEIDEN (NL) | 1999-02-04 | — | — | WO | disclosed |
| US-5856086-A | Polymerase chain reaction assays for monitoring antiviral therapy and making therapeutic decisions in the treatment of acquired immunodeficiency syndrome | LELAND STANFORD JUNIOR UNIVERSITY (US) | 1999-01-05 | — | — | US | disclosed |
| CN-1200120-A | Piperazino derivatives as neurokinin antagonists | SCHERING CORP (US) | 1998-11-25 | — | — | CN | disclosed |
| CN-1198743-A | Pyrimidine derivatives as 5HT2c-receptor antagonists | HOFFMANN LA ROCHE (CH) | 1998-11-11 | — | — | CN | disclosed |
| EP-0237362-B2 | Process for detecting specific nucleotide variations and genetic polymorphisms present in nucleic acids and kits therefor | HOFFMANN LA ROCHE (CH) | 1998-10-21 | — | — | EP | disclosed |
| WO-1998016658-A2 | PROBES, METHODS AND KITS FOR DETECTION AND TYPING OF HELICOBACTER PYLORI NUCLEIC ACIDS IN BIOLOGICAL SAMPLES | INNOGENETICS N.V. (BE) | 1998-04-23 | — | — | WO | disclosed |
| US-5728735-A | Pharmaceutical composition containing R-α-lipoic acid or S-α-lipoic acid as active ingredient | ASTA PHARMA AKTIENGESELLSCHAFT (DE) | 1998-03-17 | — | — | US | disclosed |
| WO-1998008948-A1 | PROTEIN TARGETING TO GLYCOGEN | WARNER-LAMBERT COMPANY (US) | 1998-03-05 | — | — | WO | disclosed |
| EP-0817866-A1 | METHOD FOR DETECTION OF DRUG-INDUCED MUTATIONS IN THE REVERSE TRANSCRIPTASE GENE | INNOGENETICS N.V. (BE) | 1998-01-14 | — | — | EP | disclosed |
| WO-1997040193-A2 | METHOD FOR TYPING AND DETECTING HBV | INNOGENETICS N.V. (BE) | 1997-10-30 | — | — | WO | disclosed |
| US-5665548-A | DETECTING IF A SEQUENCE ASSOCIATED WITH SUSCEPTIBILITY TO INSULIN DEPENDENT DIABETES MELLITUS OR DR4 ASSOCIATED PEMPHIGUS VULGARIS IS PRESENT IN A DNA SAMPLE | ROCHE MOLECULAR SYSTEMS, INC. (US) | 1997-09-09 | — | — | US | disclosed |
| WO-1997027332-A1 | METHOD FOR DETECTION OF DRUG-INDUCED MUTATIONS IN THE REVERSE TRANSCRIPTASE GENE | INNOGENETICS N.V. (BE) | 1997-07-31 | — | — | WO | disclosed |
| EP-0258017-B1 | Purified thermostable enzyme and process for amplifying, detecting, and/or cloning nucleic acid sequences using said enzyme | HOFFMANN LA ROCHE (CH) | 1997-06-04 | — | — | EP | disclosed |
| EP-0776970-A1 | Stable enzyme composition comprising a thermostable nucleic acid polymerase enzyme | F. Hoffmann-La Roche AG (CH) | 1997-06-04 | — | — | EP | disclosed |
| US-5631128-A | VIRICIDES USING REVERSE TRANSCRIPASE FOR TREATMENT OF AIDS AS ANTIRETROVIRAL DRUGS | LELAND STANFORD JUNIOR UNIVERSITY (US) | 1997-05-20 | — | — | US | disclosed |
| EP-0771360-A1 | METHOD FOR THE DETECTION OF THE ANTIBIOTIC RESISTANCE SPECTRUM OF MYCOBACTERIUM SPECIES | INNOGENETICS N.V. (BE) | 1997-05-07 | — | — | EP | disclosed |
| CN-1146206-A | Bicyclic thiophene derivatives and use as gonadotropin releasing hormone antagonists | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1997-03-26 | — | — | CN | disclosed |
| US-5604099-A | TREATING SAMPLE WITH PRIMERS, NUCLEOTIDE TRIPHOSPHATES AND AGENTS FOR POLYMERIZING THE TRIPHOSPHATES YIELDS EXTENSION PRODUCT OF PRIMER WHICH SEPARATES FROM ITS COMPLEMENT ON DENATURING AND ACTS AS A TEMPLATE, AMPLIFICATION | HOFFMANN-LA ROCHE INC. (US) | 1997-02-18 | — | — | US | disclosed |
| EP-0515089-B1 | Ink compositions having decreased drying times | XEROX CORP (US) | 1996-11-13 | — | — | EP | disclosed |
| US-5569670-A | ANTIDIABETIC AGENTS | ASTA MEDICA AKTIENGESELLSCHAFT (DE) | 1996-10-29 | — | — | US | disclosed |
| US-5491225-A | PCR primers for detection of legionella species and methods for controlling visual intensity in hybridization assays | HOFFMANN-LA ROCHE INC. (US) | 1996-02-13 | — | — | US | disclosed |
| WO-1995033851-A2 | METHOD FOR THE DETECTION OF THE ANTIBIOTIC RESISTANCE SPECTRUM OF MYCOBACTERIUM SPECIES | INNOGENETICS N.V. (BE) | 1995-12-14 | — | — | WO | disclosed |
| US-5468613-A | Sampling and hybridizing nucleoside triphosphates then denaturing and treating membranes | HOFFMANN-LA ROCHE INC. (US) | 1995-11-21 | — | — | US | disclosed |
| EP-0459532-B1 | Primers and probes for nucleic acid detection | HOFFMANN LA ROCHE (CH) | 1995-07-19 | — | — | EP | disclosed |
| US-5334612-A | Solid, semisolid, solution, suspension or emulsion dosage unit | ASTA PHARMA AKTIENGESELLSCHAFT (DE) | 1994-08-02 | — | — | US | disclosed |
| EP-0533854-A4 | PCR PRIMERS FOR DETECTION OF LEGIONELLA SPECIES AND METHODS FOR CONTROLLING VISUAL INTENSITY IN HYBRIDIZATION ASSAYS | HOFFMANN LA ROCHE (CH) | 1994-06-08 | — | — | EP | disclosed |
| EP-0439458-B1 | CHARACTERIZATION AND DETECTION OF SEQUENCES ASSOCIATED WITH AUTOIMMUNE DISEASES | HOFFMANN LA ROCHE (CH) | 1994-06-01 | — | — | EP | disclosed |
| EP-0537222-A1 | IMMUNOREACTIVE COMPOUND | AKZO N.V. (NL) | 1993-04-21 | — | — | EP | disclosed |
| EP-0533854-A1 | PCR PRIMERS FOR DETECTION OF LEGIONELLA SPECIES AND METHODS FOR CONTROLLING VISUAL INTENSITY IN HYBRIDIZATION ASSAYS | F. HOFFMANN-LA ROCHE AG (CH) | 1993-03-31 | — | — | EP | disclosed |
| EP-0515089-A1 | Ink compositions having decreased drying times | XEROX CORPORATION (US) | 1992-11-25 | — | — | EP | disclosed |
| WO-1992011273-A1 | PCR PRIMERS FOR DETECTION OF LEGIONELLA SPECIES AND METHODS FOR CONTROLLING VISUAL INTENSITY IN HYBRIDIZATION ASSAYS | F.HOFFMANN-LA ROCHE AG (CH) | 1992-07-09 | — | — | WO | disclosed |
| US-5100469-A | Colorant, carrier and meso-erythritol or a trihydroxy compound | XEROX CORPORATION (US) | 1992-03-31 | — | — | US | disclosed |
| EP-0263526-B1 | METHOD OF PURIFYING TOXIN CONJUGATES USING HYDROPHOBIC INTERACTION CHROMATOGRAPHY | CETUS ONCOLOGY CORPORATION (US) | 1992-03-25 | — | — | EP | disclosed |
| WO-1992000763-A1 | IMMUNOREACTIVE COMPOUND | AKZO N.V. (NL) | 1992-01-23 | — | — | WO | disclosed |
| EP-0459533-A2 | Probe groups for the detection of nucleotide variations and genetic polymorphisms | F. HOFFMANN-LA ROCHE AG (CH) | 1991-12-04 | — | — | EP | disclosed |
| EP-0459532-A2 | Primers and probes for nucleic acid detection | F. HOFFMANN-LA ROCHE AG (CH) | 1991-12-04 | — | — | EP | disclosed |
| EP-0439458-A1 | CHARACTERIZATION AND DETECTION OF SEQUENCES ASSOCIATED WITH AUTOIMMUNE DISEASES. | CETUS CORP (US) | 1991-08-07 | — | — | EP | disclosed |
| US-4965188-A | REACTING NUCLEIC ACID WITH OLIGONUCLEOTIDE PRIMER IN PRESENCE OF CATALYTIC ENZYME DNA POLYMERASE; POLYMERASE CHAIN REACTION PATENT | CETUS CORPORATION (US) | 1990-10-23 | — | — | US | disclosed |
| WO-1989004875-A2 | CHARACTERIZATION AND DETECTION OF SEQUENCES ASSOCIATED WITH AUTOIMMUNE DISEASES | CETUS CORPORATION (US) | 1989-06-01 | — | — | WO | disclosed |
| US-4771128-A | Method of purifying toxin conjugates using hydrophobic interaction chromatography | CETUS CORPORATION (US) | 1988-09-13 | — | — | US | disclosed |
| EP-0263526-A1 | Method of purifying toxin conjugates using hydrophobic interaction chromatography | CETUS ONCOLOGY CORPORATION (US) | 1988-04-13 | — | — | EP | disclosed |
| EP-0258017-A2 | Purified thermostable enzyme and process for amplifying, detecting, and/or cloning nucleic acid sequences using said enzyme | F. HOFFMANN-LA ROCHE AG (CH) | 1988-03-02 | — | — | EP | disclosed |
| EP-0237362-A1 | Process for detecting specific nucleotide variations and genetic polymorphisms present in nucleic acids and kits therefor | F. HOFFMANN-LA ROCHE AG (CH) | 1987-09-16 | — | — | EP | disclosed |
| EP-0230363-A2 | Process for labeling single-stranded nucleic acids and hybridization probes | CETUS CORPORATION (US) | 1987-07-29 | — | — | EP | disclosed |
| US-4681853-A | Perfusion slit chamber for filter-bound sample analyses | HOEFER, INC. | 1987-07-21 | — | — | US | disclosed |
| US-4645747-A | SEPARATION OF FREE GAMMA-LABELLED LIGAND FROM BOUND BY SOLVENT EXTRACTION | TECHNION RESEARCH & DEVELOPMENT FOUNDATION, LTD. (IL) | 1987-02-24 | — | — | US | disclosed |
| EP-0210863-A1 | Immunoassay | MODERN DIAGNOSTICS, INC. (US) | 1987-02-04 | — | — | EP | disclosed |
| EP-0206779-A1 | Detecting antinuclear antibody | MODERN DIAGNOSTICS, INC. (US) | 1986-12-30 | — | — | EP | disclosed |
| US-4454231-A | Method and device for mass transfer operation in immunoassays and other applications | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION, LTD. (IL) | 1984-06-12 | — | — | US | disclosed |
| US-4279934-A | Method for improving the odor, flavor and color of canned ocean clam products | THE AMERICAN ORIGINAL CORPORATION (US) | 1981-07-21 | — | — | US | disclosed |
| US-4250161-A | Method and kit for the preparation of radiopharmaceuticals | SOLCO BASEL AG (CH) | 1981-02-10 | — | — | US | disclosed |
| US-4250161-A | Method and kit for the preparation of radiopharmaceuticals | SOLCO BASEL AG (CH) | 1981-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010039292-A1 | Lipoic acid analogs | ALOX5, ALOX15, ACSL5 | ADRA1A 1115/4885TDP1 3829/4885EYA2 3414/4885 |
| US-20100317639-A1 | Medicament Based On a Monoester of Steroids With Long Chain Fatty Acids | ACAT1, ACAT2, HSD17B12 | ADRA1A 180/4885TDP1 3847/4885EYA2 2882/4885 |
| US-20090068651-A1 | Method for the detection of the antibiotic resistance spectrum of mycobacterium species | POLR2A, POLR2B, NOP2 | ADRA1A 3095/4885TDP1 1221/4885EYA2 3618/4885 |
| US-20130261137-A1 | Methods, Compounds and Compositions Relating to Activating a Latent Virus | MAP1LC3A, PML, MAP1LC3B | ADRA1A 3517/4885TDP1 259/4885EYA2 1804/4885 |
| US-20070054902-A1 | Isoxazole derivatives as peroxisome proliferator-activated receptors agonists | NR1H3, NR1H2, RXRA | ADRA1A 227/4885TDP1 4483/4885EYA2 3865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.